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Abstract 
Epidermal growth factor receptor (EGFR) plays such a crucial role in cell signaling that its 
activity is intricately regulated. According to the prevailing activation model, EGF binding 
to EGFR initiates a series of structural rearrangements, leading to allosteric activation of 
the kinase domain. During this process the oligomeric state of the kinase is promoted from 
monomer or inactive (symmetric) dimer to active (asymmetric) dimer. Due to the direct 
correlation with kinase activity, asymmetric/symmetric dimers are key to this activation 
model, and therefore have been extensively studied via crystallography and negative-stain 
electron microscopy. However, high-resolution structural description of these entities in 
solution is still lacking. Here, via pulsed electron-electron double resonance (PELDOR) 
spectroscopy, a number of different EGFR constructs are shown to exist in solution in a 
single oligomeric form that reflects asymmetric dimerization as reported in crystallization 
studies. Mutagenesis and analytical gel filtration studies corroborate this dimeric 
arrangement. Notably, a new approach to label proteins for PELDOR studies, i.e. inhibitor-
directed spin labeling, has been established in this pilot study of EGFR, which exemplifies 
its potential for a more general application in PELDOR-based protein conformation 
studies. Beyond the well-established model of receptor-intrinsic control of the allosteric 
activation mechanism, evidence is accumulating for an additional layer of regulation of 
EGFR activity by less well-understood cytoplasmic modulators. Therefore, the second part 
of this thesis is devoted to investigating interaction of EGFR with Arf nucleotide-binding 
site opener (ARNO), a potential activator, via microscale thermophoresis (MST) and 
nuclear magnetic resonance (NMR) studies. MST assays not only reveal EGFR:ARNO 
interaction, but also identify the recognition elements as the Sec7 domain of ARNO and 
the juxtamembrane (JM) segment of EGFR. Competition experiments demonstrate that 
calmodulin, another EGFR activity modulator, targets the same or a similar binding site in 
JM yet with stronger affinity compared to Sec7. NMR studies characterize the amino acids 
of Sec7 and JM that are involved in their interaction and narrow down the binding sites of 
Sec7 and calmodulin to the same N-terminal region in JM. To integrate the results of 
these studies into the current view of EGFR signaling an “endocytosis hypothesis” and a 
“priming hypothesis” are presented. 
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1 Introduction 
1.1 EGFR: introduction and signaling pathways  
Epidermal growth factor receptor (EGFR) is a single-pass transmembrane protein from 
HER/ErbB family (HER for human EGF receptor and ErbB named after related avian 
erythroblastosis oncogene B), which also includes another three members, i.e. 
HER2/ErbB2/Neu, catalytically impaired HER3/ErbB3 and HER4/ErbB4. EGFR plays such 
a key role in cell growth, proliferation, migration and differentiation, that its deregulation is 
often related to carcinogenesis (reviewed by Yarden and Sliwkowski, 2001). As a type I 
transmembrane protein, EGFR is expressed in its nascent form containing 24-residue 
signal peptide, which is cleaved off in endoplasmic reticulum (ER), leading to mature 
EGFR (Ullrich et al., 1984). In this thesis, sequence numbering for EGFR will exclude the 
signal peptide. As a receptor tyrosine kinase (RTK), EGFR contains EGF-binding 
extracellular domain (ECD) and kinase-harboring intracellular domain (ICD) which are 
separated by the helical transmembrane domain (TM). ICD is subdivided into 
juxtamembrane domain (JM), kinase domain and autophosphorylation site-containing C-
terminal tail (CT), with first and second halves of JM being named JM-A and JM-B, 
respectively (Figure 1.1). Notably, a segment dubbed as “kinase core”, which incorporates 
parts of JM-B and CT and spans residue 672-998, is extensively studied as the integrated 
kinase unit (Jura et al., 2009; Park et al., 2015; Stamos et al., 2002; Yun et al., 2007; 
Zhang et al., 2006, 2007).  
 
Figure 1.1 Domain sketch of full length EGFR. Sequence numbering is based on human EGFR 
without signal peptide. Note that depicted autophosphorylation sites are representative yet 
incomplete. Figure is taken from Jura et al., 2009.  
Ligand-induced dimerization is the fundamental idea of canonical model for EGFR 
activation, in which binding of EGF to ECD mediates EGFR dimerization, and thereby 
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activates its kinase domain and leads to autophosphorylation at CT tyrosines (Yarden and 
Schlessinger, 1987b, 1987a). Right at the hub of signal transduction, activated EGFR 
triggers multitudes of signaling pathways, among which the major ones are Ras-Raf-MEK-
ERK, PLCγ-PKC and PI3K-Akt-mTOR pathways. In general, these pathways are initiated 
through recognition of phosphotyrosines on EGFR by SH2 (Src Homology 2) or PTB 
(phosphotyrosine binding) domains of effector proteins (reviewed by Pawson, 2004). In 
Ras-Raf-MEK-ERK pathway, such effector is Grb2 (growth factor receptor-bound protein 
2), which docks onto certain phosphotyrosines via its SH2 domain. Grb2 in turn recruits 
SOS (son of sevenless) through its SH3 (Src Homology 3) domain. SOS functions as 
guanine nucleotide exchange factor (GEF) to activate GTPase Ras (rat sarcoma), which 
relays the activation signal further downstream through a chain of phosphorylation 
reactions, leading to sequential activations of Raf (rapidly accelerated fibrosarcoma), MEK 
(MAPK/ERK kinase) and ERK (extracellular-signal regulated kinase). Similarly, PLCγ 
(phospholipase C γ) binds to specific EGFR phosphotyrosines via its SH2 domain. 
Recruited active PLCγ hydrolyzes plasma membrane-embedded PIP2 
(phosphatidylinositol 4,5-bisphosphate) into DAG (diacylglycerol) and IP3 (inositol 1,4,5-
triphosphate). IP3, upon binding to Ca2+ channel on ER, releases its Ca2+ store into 
cytosol. Ca2+ and DAG activate PKC (protein kinase C) together. PI3K-Akt-mTOR 
cascade is triggered in a slightly different way. Instead of direct docking, PI3K 
(phosphatidylinositol-3-kinase) is recruited to activated EGFR via Grb2 and GAB1 (Grb2-
associated-binding protein 1). Activated PI3K catalyzes phosphorylation of PIP2 into PIP3 
(phosphatidylinositol 3,4,5-trisphosphate), and PIP3 facilitates recruitment of Akt (also 
known as protein kinase B, PKB) to plasma membrane. Thereafter, Akt and mTOR 
(mammalian target of rapamycin) are sequentially phosphorylated and activated. ERK, 
PKC and mTOR mediate various cellular processes in response to extracellular 
stimulation of growth factor (reviewed by Wee and Wang, 2017; reviewed by Yarden and 
Sliwkowski, 2001).  
1.2 Catalytic mechanism of EGFR kinase  
As a receptor tyrosine kinase, EGFR harbors in its cytoplasmic department a kinase 
domain, which upon activation catalyzes phosphoryl transfer reaction between adenosine 
5’-triphosphate (ATP) and specific tyrosines on EGFR. The kinase core is composed of N-
lobe and C-lobe. During the reaction, ATP is sandwiched between these two lobes and 
surrounded by key regulatory and catalytic elements from both sides. According to 
previous structural studies, N-lobe is mainly composed of β-strands while C lobe is highly 
helical (Blair et al., 2007; Jura et al., 2009; Stamos et al., 2002; Zhang et al., 2006). To 
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appreciate the catalytic mechanism of EGFR, a crystal structure from one of those studies 
is presented in Figure 1.2 (A), which displays EGFR kinase in active conformation, 
complexed with an ATP analog-peptide conjugate (PDB ID:2GS6; Zhang et al., 2006). An 
inactive kinase from the same study, bearing V924R mutation and complexed with ATP 
analog AMP-PNP, is presented in Figure 1.2 (B) for comparison (PDB ID: 2GS7). As 
common practice, secondary structure of EGFR kinase core follows the nomenclature of 
protein kinase A (Taylor and Radzio-Andzelm, 1994; Zhang et al., 2006).  
 
Figure 1.2 Crystal structures of EGFR kinase in active (A) or inactive conformation (B). Wildtype 
kinase core, i.e. ICD(672-998), in (A) and its inactivating mutant V924R in (B) are depicted as dark 
green and dark blue cartoons, respectively. Corresponding ligands on ATP-binding sites are 
labeled below the figure, and shown as sticks with carbons colored yellow. Relevant residues are 
labeled and shown as sticks with carbons colored magenta. Mg2+ ion is depicted as a green sphere 
in (B), and it is missing in (A) due to technical reason. Activation loops are colored orange and αC-
helices are shown as pink. Glycine-rich loops are colored dark blue (A) or dark green (B). Note the 
different orientations of αC-helices in (A) and (B), and the distinct activation loop structure in (B) 
compared to (A). AMP-PNP: Adenosine 5′-(β,γ-imido)triphosphate. Figure was prepared from PDB 
ID: 2GS6 (A) and 2GS7 (B) with PyMOL Molecular Graphics System. 
For N-lobe, five β-strands (β1-β5) are organized into an antiparallel β-sheet. β1- and β2-
strands are connected by a flexible glycine-rich loop (also known as P-loop),  which 
approaches triphosphate moiety to facilitate ATP orientation, while V702 and A719 from 
β2- and β3-strands, together with L820 from C-lobe, accommodate adenine moiety via 
hydrophobic contacts. Connecting β3- and β4-strands on the sequence, αC-helix plays a 
central role in EGFR kinase activation. E738 in the middle of αC-helix forms a salt bridge 
Activation loop
Glycine-rich loop
N-lobe
C-lobe
Activation loop
αC-helix
αC-helix
A B
K721
K721E738
D831
D813
E738
D831
D813
Glycine-rich loop
Mg2+
WT kinase &
ATP analog-peptide conjugate
Kinase (V924R)
& AMP-PNP
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with K721 on β3-strand, which in turn interacts with α- and β-phosphates to facilitate ATP 
binding. The K721-E738 salt bridge maintains “αC-helix in” conformation, an essential 
configuration of active kinase.  
C-lobe of kinase core is primarily composed of six helices (αD-αI). Based on the 
sequence, catalytic loop and activation loop (also known as A-loop) lie between αE- and 
αF-helices. On catalytic loop (residue 811-818), a region three amino acids downstream 
of αE-helix, catalytic residue D813 of HRD motif acts as a base to deprotonate hydroxyl 
group on tyrosine, promoting its nucleophilic attack towards γ-phosphate of ATP. 
Activation loop (residue 831-852) begins with D831 of DFG motif, which coordinates an 
Mg2+ ion together with α- and β-phosphates and thereby promotes ATP binding. 
Altogether, K721, E738, D813 and D831 are considered as the most critical components 
of catalytic and regulatory machinery of EGFR kinase (reviewed by Roskoski, 2014), and 
it will be explained in next section concerning how these residues come into position for 
phosphorylation, in response to the signal beyond plasma membrane.   
1.3 Allosteric activation and autoinhibition of EGFR  
Comparing (A) and (B) in Figure 1.2 reveals that the major structural differences can be 
narrowed down to changes in two regions, i.e. αC-helix and activation loop. In active 
kinase structure, αC-helix is leaning towards ATP-binding site and forming K721-E738 salt 
bridge (“αC-helix in” conformation), while activation loop adopts an extended and open 
conformation suited for substrate docking. Yet in inactive conformation, αC-helix rotates 
away with K721-E738 salt bridge disrupted (“αC-helix out” conformation), while activation 
loop is coiled and closed, typically with a newly-formed short helix (residue 833-838) at 
the beginning of the loop, packing against αC-helix to stabilize its position in “αC-helix out” 
form. Taken together, active EGFR kinase adopts “αC-helix in” and “activation loop open” 
form, whereas inactive one displays “αC-helix out” and “activation loop closed” form. 
Additionally, in both kinase structures, D831 of DFG motif face towards ATP-binding site, 
a conformation known as “DFG-in”. In general, inactive conformations across different 
protein kinases are quite diverse, in contrast to active kinases, which share the highly 
conserved conformation due to structural restraints required for catalysis of common 
reaction, i.e. protein phosphorylation (reviewed by Jura et al., 2011). As for EGFR kinase, 
its inactive structure resembles that of Src kinase (PDB ID: 2SRC; Xu et al., 1999) or 
cyclin-dependent kinase (CDK for short; PDB ID: 1HCL; De Bondt et al., 1993), hence the 
name “Src/CDK-like inactive conformation” for this structure (reviewed by Jura et al., 
2011; Zhang et al., 2006).  
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Figure 1.3 Crystal structures of EGFR kinase in asymmetric (active) dimer conformation. Kinase 
core, i.e. ICD(672-998), is depicted as dark green or dark blue cartoon in either monomer. ATP 
analog-peptide conjugate in receiver is shown as sticks with carbons colored yellow. Relevant 
residues are labeled and shown as sticks with carbons colored magenta. Activation loop of receiver 
is colored orange, receiver αC-helix pink and activator αH-helix yellow. Figure was prepared from 
PDB ID: 2GS6 with PyMOL Molecular Graphics System.  
Kinase activation is a process of structural transition from inactive to active conformation, 
during which most other RTKs require tyrosine phosphorylation on the activation loop to 
relieve its occlusion at the ATP- or substrate-binding site. Untypically, this step is not 
necessary for EGFR kinase activation, which instead involves an allosteric mechanism 
(reviewed by Hubbard and Miller, 2007; reviewed by Lemmon and Schlessinger, 2010; 
Gotoh et al., 1992; Stamos et al., 2002; Zhang et al., 2006). According to this mechanism, 
one kinase molecule (“activator”) allosterically activates another (“receiver”) by forming an 
active dimer, in which C-lobe of the activator packs against N-lobe of the receiver. Due to 
the head-to-tail orientation of molecules, active dimer is also referred to as asymmetric 
dimer. Upon dimerization, αH-helix of activator contacts αC-helix of the receiver and shifts 
it to “αC-helix in” position, restoring the critical K721-E738 salt bridge for ATP binding. 
Rotation of αC-helix also disengages itself from interaction with the short helix on 
activation loop, which “relaxes” the loop to open conformation for substrate docking 
(Figure 1.3). The way that activator triggers structural movement of receiver via its impact 
on αC-helix, is very similar to the activation of CDK2 by cyclin A (Jeffrey et al., 1995). 
Moreover, further studies indicate that JM segment stabilizes the asymmetric dimer and 
contributes greatly to the kinase activity. Part of receiver JM-B (residue 664-672), known 
Activation loop
αC-helix
αH-helix
K721
E738
D831
D813
Activator C-lobe Activator N-lobe
Receiver N-lobe
Receiver C-lobe
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as “juxtamembrane latch”, “cradles” the C-lobe of activator and thereby maintains the 
dimer in its asymmetric form (Figure 1.4; Jura et al., 2009; Red Brewer et al., 2009). 
Additionally, JM-A segment forms antiparallel helical dimer in active kinase, further 
stabilizing the asymmetric dimer (Endres et al., 2013; Jura et al., 2009). Therefore, a 
construct containing only EGFR kinase and JM is intrinsically active, with activity in 
solution increased by almost 70-fold due to JM (Jura et al., 2009).    
 
Figure 1.4 Crystal structure of EGFR kinase to reveal juxtamembrane latch. ICD(645-998) bearing 
K721M mutation is depicted as dark green or dark blue cartoon in either monomer. In activator, 
fragment spanning residue 645-671 is omitted. αC-helix of receiver is colored pink, αH-helix of 
activator yellow, and juxtamembrane latch magenta. Figure was prepared from PDB ID: 3GOP 
(Red Brewer et al., 2009) with PyMOL Molecular Graphics System.   
In contrast, activity of full length EGFR, which is more than a mere kinase protein, is 
normally kept at bay in resting phase and only boosted upon stimulation by growth factors. 
Regulation of EGFR activity is very crucial, as evidenced by constitutive activation of 
EGFR often observed in various cancer conditions (reviewed by Masuda et al., 2012; 
reviewed by Roskoski, 2014; reviewed by Soria et al., 2012). As will be introduced, 
multiple layers of delicate autoinhibition mechanisms in EGFR have been evolved by 
nature and coupled together to regulate its activity, so EGFR activation is a chain of 
events to loosen up these inhibitory restraints so that kinase domain can dimerize in 
active form and initiate signal transduction by autophosphorylation. Activation and 
inhibition are like two sides of a coin. To appreciate the activation process, autoinhibition 
αH-helix
αC-helix
Juxtamembrane latch
Activator C-lobe
Activator N-lobe
Receiver N-lobe
Receiver C-lobe
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should be clarified first. Three major inhibitory elements for EGFR activity are present, i.e. 
ECD obstruction, electrostatic attraction to anionic lipids and CT hindrance.  
ECD of EGFR functions like a scout, posted beyond the plasma membrane, ready to 
collect the signal from rapidly changing cell exterior and relay it to the interior. To achieve 
this, binding of ligand such as EGF induces ECD dimerization as the first step. Among 
RTKs, dimer interface of ECD can be composed of ligand alone as in the case of nerve 
growth factor receptor (Urferl et al., 1995; Wlesmann et al., 1999), ligand together with 
receptor as in the case of stem cell factor receptor c-Kit (Blechman et al., 1995; Lev et al., 
1993) or ECD is constitutively dimerized as in insulin receptor (reviewed by De Meyts, 
2008; reviewed by Ward et al., 2007). In contrast, EGFR-ECD dimerization interface 
solely consists of receptor contacts (reviewed by Endres et al., 2014; reviewed by 
Lemmon et al., 2014). ECD of EGFR is subdivided into domain I (residue 1-165), domain 
II (residue 166-310), domain III (residue 311-480) and domain IV (residue 481-620). 
Domain I and III are both leucine-rich and share a rigid β-helix structure, while domain II 
and domain IV adopt extended structures and are rich in cysteines, which form disulfide 
bridges (reviewed by Roskoski, 2014). Upon stimulation, EGF binds simultaneously to 
domain I and III of the same EGFR molecule. The binding event brings those two domains 
closer and thereby promotes a global rotation of domain I and II to expose the 
dimerization arm, a β-hairpin in domain II that mediates ECD dimerization (PDB ID: 3NJP; 
Lu et al., 2010). In the autoinhibited state, however, ECD exists in a “tethered” form with 
this β-hairpin making intramolecular contact with domain IV, which obstructs ECD 
dimerization (PDB ID: 1NQL; reviewed by Burgess et al., 2003; Ferguson et al., 2003). 
Since EGF is not required as part of dimer interface, ECD obstruction is crucial in 
preventing ECD from ligand-independent dimerization (reviewed by Endres et al., 2014).  
The second autoinhibition mechanism involves electrostatic attraction between JM and 
anionic lipids. Previous studies indicate that anionic lipids on the inner leaflet of plasma 
membrane interacts with positively charged JM, especially JM-A segment (Aifa et al., 
2002; Sato et al., 2006; Sengupta et al., 2009). This electrostatic attraction tethers JM to 
the plasma membrane, hindering its activating functions such as JM-A antiparallel helical 
dimerization and juxtamembrane latching. Correspondingly, a TM-JM structural coupling 
mechanism has been proposed to relieve JM from its tethered state (Arkhipov et al., 2013; 
Endres et al., 2013). In the cell exterior, EGF-induced dimerization rearranges domain IV 
of ECD into a V shape, which leads to contact between C-termini of two ECDs and close 
proximity of N-termini of TM helical dimer. This in turn pulls JM-A off plasma membrane, 
promoting its antiparallel helices formation, reorientation of kinases into asymmetric dimer 
and allosteric activation, probably with the help of a cellular modulator, i.e. calmodulin, via 
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competitive binding to JM (McLaughlin et al., 2005). In contrast, during resting phase, N-
termini of TM helices are kept at distance due to ECD obstruction, which renders TM in 
either monomeric state, or inactive dimeric state with C-termini of TM in proximity and JM 
tethered. This concerted movement of TM and JM delicately connects ECD dimerization 
to kinase activation, so that extracellular signal effectively passes through membrane and 
elicits cellular responses (Arkhipov et al., 2013; Endres et al., 2013). 
 
Figure 1.5 Crystal structure of EGFR kinase to reveal CT autoinhibition. Kinase B and C (PDB ID: 
3GT8), containing kinase core with inactivating V924R mutation, are oriented as symmetric dimer  
and depicted as dark blue and dark green cartoons, respectively. Kinase A (PDB ID: 3GOP), 
containing ICD(645-998) with K721M mutation, is positioned relative to Kinase B following 
asymmetric dimer orientation and depicted as lemon green cartoon. Ligands on ATP-binding sites 
are omitted. αC-helices are colored pink, electrostatic hook from Kinase B magenta, and 
juxtamembrane latch from Kinase A orange. AP-2 helices and the structural clash between JM and 
CT are labeled. Figure was prepared from PDB ID: 3GT8 and 3GOP with PyMOL Molecular 
Graphics System.  
CT hindrance represents the third EGFR autoinhibition mechanism, in which CT blocks 
the JM-mediated active dimerization. In a previous study, EGFR kinase bearing an 
deactivating mutation V924R was crystallized, which contains the key structural elements 
of inactive kinase described before (PDB ID: 3GT8; Jura et al., 2009).  As shown in Figure 
1.5, CT of kinase B folds back to kinase domain with AP-2 helix (residue 967-978; AP-2 
for adaptor protein 2) approaching hinge region behind the ATP-binding site. Seven 
residues following AP-2-helix are dubbed as “electrostatic hook”, because they are highly 
acidic, containing four aspartates and two glutamates, and attracted to basic residues at 
αC-helix
αC-helix
AP-2 helices
αC-helix
Juxtamembrane latch
Electrostatic hook
Structural clash
Kinase B
Kinase C
Kinase A
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the kinase surface. Residues further downstream are thereby “pinned” by electrostatic 
hook onto the C-lobe of kinase B, with their binding region overlapping with that of 
juxtamembrane latch. This structural clash with JM can hinder asymmetric dimer 
formation and explain the autoinhibitory effect of CT. When charge-reversing mutations 
were introduced in electrostatic hook, the basal phosphorylation of EGFR was enhanced 
(Jura et al., 2009). Meanwhile, other studies also corroborate the autoinhibitory role of CT 
(Bublil et al., 2010; Frederick et al., 2000; Pines et al., 2010; Wood et al., 2004). 
Furthermore, two inactive kinases (B and C) in Figure 1.5 are oriented in head-to-head 
fashion, and hence named “symmetric dimer”, with AP-2 helices contributing greatly to the 
dimeric interface. Such a symmetric arrangement is also observed in negative-stain EM 
studies (Lu et al., 2012; Mi et al., 2011), and proposed as the favored dimeric form under 
ligand-free conditions (Arkhipov et al., 2013). Considering that preformed EGFR dimer on 
the cell surface has been reported before (Sako et al., 2000; Yu et al., 2002), this 
symmetric autoinhibited dimer could be one of the inactive forms for EGFR prior to 
stimulation, especially in cancer conditions, where EGFR is often overexpressed (Masuda 
et al., 2012; Soria et al., 2012).   
 
Figure 1.6 Activation scheme of EGFR. JM tethering and C-termini dimerization of TM in inactive 
states are not visualized. Figure is taken from Jura et al., 2009.  
Combining aforementioned autoinhibition mechanisms leads to a full picture of EGFR 
activation. To begin with, extracellular binding of EGF gives rise to rotation of domain I 
and II, exposing dimerization arms and promoting ECD dimerization. Consequently, the V-
shape orientation of dimerized domain IV results in N-termini dimerization of TM 
segments, which is coupled to JM dissociation from plasma membrane. Untethered JM 
facilitates rearrangement of kinase domain from either monomer or symmetric (inactive) 
dimer to asymmetric (active) dimer, relieving the CT autoinhibition and promoting 
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allosteric activation of EGFR kinase via antiparallel helical dimerization of JM-A and 
juxtamembrane latching of JM-B (Figure 1.6).  
1.4 EGFR downregulation 
Once EGFR is stimulated and activated, it initiates various signaling pathways as 
described in section 1.1. However, the signal transduction needs to be contained to avoid 
overstimulation. To accomplish this, cells have established multiple safeguarding systems 
to internalize EGFR, quench its signal and in the end recycle or degrade the receptor. 
This process, also known as EGFR downregulation, is mediated by several endocytic 
pathways.  
First endocytosis route is suited for EGFR species sporadically activated in EGF-free 
conditions. In this case, GTPase Rab11 mediates EGFR uptake and returns it back to the 
plasma membrane via recycling endosome. This endocytic route effectively collects and 
recycles aberrantly activated EGFR to maintain EGFR abundance on the cell surface. 
(reviewed by Bakker et al., 2017; Ullrich et al., 1996). Additionally, as activated EGFR 
travels towards cell interior, it gradually becomes dephosphorylated due to the activity of 
ER-located PTP1B (protein-tyrosine phosphatase 1B; Eden et al., 2010). Thereafter, 
recycled EGFR resumes unphosphorylated, inactive form, ready for the next activating 
event. Second endocytosis route is applied to the situation where EGFR is stimulated by 
low concentrations of EGF and triggers clathrin-dependent endocytosis (Sigismund et al., 
2005). Upon EGFR activation, AP-2 docks onto its recognition motif, i.e. AP-2 helix in 
EGFR-CT, which is sequestered before in inactive forms of EGFR (Jura et al., 2009; 
Sorkin and Carpenter, 1993; Sorkin et al., 1996). AP-2 attracts clathrin and thereby 
recruits EGFR to clathrin-coated pits, which later buds into cytosol as clathrin-coated 
vesicles (reviewed by Robinson, 2015). Interestingly, this budding process enriches EGFR 
locally and thus potentiates its autophosphorylation (Ibach et al., 2015). Furthermore, 
these vesicles are fused to Rab5-regulated early endosome, where EGFR is still able to 
maintain its signaling to downstream effectors (reviewed by Murphy et al., 2009; reviewed 
by Villaseñor et al., 2016; Tomshine et al., 2009; Wang et al., 2002). Therefore, both 
mechanisms enhance the sensitivity of EGFR in response to low-dose stimulation. EGFR, 
activated as such, is later dephosphorylated and returned back to cell surface through 
recycle endosome (reviewed by Bakker et al., 2017). Third endocytosis route takes place 
when high levels of EGF stimulates the receptor and leads to its degradation. In contrast 
to second pathway, EGFR endocytosis via third route is typically clathrin-independent and 
involves ubiquitination (Sigismund et al., 2005). EGFR is ubiquitinated by Cbl, which 
efficiently binds to highly phosphorylated EGFR via Grb2 and functions as ubiquitin-
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protein ligase E3 to transfer ubiquitin from ubiquitin-conjugating enzyme E2 to EGFR 
(reviewed by Roskoski, 2014; Jiang, 2003; Levkowitz, 1996). Modified EGFR is 
transported via early endosome to Rab7-regulated late endosome, with the help of 
ESCRTs (endosomal sorting complexes required for transport). Thereafter, late 
endosome engulfs EGFR into ILV (intraluminal vesicles) to form MVB (multivesicular 
body). Contrary to the orientation in early endosome, EGFR-ICD faces towards the inside 
of ILVs, which spatially prohibits any contact with cytoplasmic effectors for further 
signaling. As the final step, fusion of MVB and protease-rich lysosome brings EGFR to its 
doom (reviewed by Bakker et al., 2017).  
In addition to three endocytic pathways, other mechanisms are also involved in EGFR 
downregulation. Proteasome has been reported to facilitate degradation via de-
ubiquitination prior to proteolysis in lysosome (Alwan et al., 2003). Furthermore, Mig6 
(mitogen-induced gene 6), a negative modulator of EGFR, occupies C-lobe side of the 
asymmetric dimer interface and thereby inhibits kinase activity (Hackel et al., 2001; Zhang 
et al., 2007). In addition, it has been indicated that another segment of Mig6 inhibits EGFR 
activation by recognizing the binding site of juxtamembrane latch on kinase C-lobe (Jura 
et al., 2009).  
1.5 Introduction of ARNO 
ARNO (Arf nucleotide-binding site opener) belongs to cytohesin family, which includes 
four homologous members, i.e. cytohesin-1, cytohesin-2 (ARNO), cytohesin-3 (also 
known as Grp1 for general receptor of phosphoinositides 1) and cytohesin-4. The family 
name “cytohesin” is derived from its founding member cytohesin-1, a cytoplasmic activator 
of αLβ2 integrin which mediates cell adhesion (Kolanus et al., 1996). All four family 
members share a common domain layout, which features a central Sec7 domain flanked 
by coiled-coil domain upstream and PH (pleckstrin homology) domain downstream. Sec7 
domain is homologous to yeast Sec7p and it functions as GEF for Arf (ADP-ribosylation 
factor) GTPases (Cox et al., 2004; Meacci et al., 1997). Coiled-coil domain induces 
protein dimerization and interacts with other proteins for either cytohesin regulation or 
downstream functions (reviewed by Kolanus, 2007; DiNitto et al., 2007), while PH domain 
is in charge of membrane recruitment via its affinity towards phosphoinositides (Klarlund 
et al., 2000). Additionally, PH domain is adjacent to Sec7-PH linker at the N-terminus and 
a helix at the C-terminus, with C-terminal helix overlapping with the polybasic region 
(PBR), an autoinhibitory motif in GEF regulation (DiNitto et al., 2007).   
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Unlike cytohesin-1 and cytohesin-4, which are mainly distributed in leukocytes, ARNO and 
Grp1 are ubiquitously expressed (reviewed by Casanova, 2007), indicating their relevance 
to more general cellular functions. Due to their central role in Arf activation via guanine 
nucleotide exchange, cytohesins participate in Arf-regulated processes such as vesicular 
traffic and cytoskeleton remodeling (reviewed by D’Souza-Schorey and Chavrier, 2006; 
reviewed by Kolanus, 2007). Furthermore, according to a previous study, an aptamer 
recognizing coiled-coil and Sec7 domain of ARNO effectively inhibits the serum-induced 
transcriptional activation and ERK1/2 activity (Theis et al., 2004). In another study, 
SecinH3, an Sec7-targeting inhibitor developed from aptamer displacement screen, 
induces insulin resistance in human liver cells (Hafner et al., 2006). Therefore, these 
studies point to the involvement of ARNO in both ERK activation and insulin signaling. 
Additionally, ARNO has been reported to be involved in G protein-independent signaling 
of GPCR (G protein-coupled receptor) via direct binding (Gsandtner et al., 2005), 
regulation of vesicle transport via interaction with V-ATPase (Hurtado-Lorenzo et al., 
2006), and crosstalk to receptor signaling via binding to adaptor proteins such as 
cytohesin interacting protein (Cytip; Boehm et al., 2003). Altogether, these examples from 
various perspectives prove the versatile role played by ARNO in cells.  
1.6 Guanine nucleotide exchange mechanism of ARNO 
As the core of ARNO, Sec7 domain possesses guanine nucleotide exchange activity for 
Arf, a group of GTPases from Ras superfamily. Arf is renowned for its role in vesicular 
traffic via recruiting coating complex onto the intracellular vesicles or activating lipid-
regulating enzymes (reviewed by Casanova, 2007), and it functions as a molecular switch, 
cycling between GDP-bound inactive form and GTP-bound active form. GEF accelerates 
substitution of GTP for GDP to turn on the Arf activity, while GAP (GTPase-activating 
protein) stimulates the intrinsic GTPase activity of Arf, promoting hydrolysis of bound GTP 
and turning off its activity. Arf activation can be divided into GDP-releasing phase and 
GTP-binding phase. ARNO stimulates GDP release in the first phase so that new 
nucleotide can bind thereafter. In the second phase, GTP is preferred to enter the empty 
nucleotide-binding site, since cellular concentration of GTP is much higher than that of 
GDP (reviewed by Traut, 1994).  
ARNO accelerates the first phase by employing a conserved glutamate (dubbed as 
“glutamic finger”) from Sec7 domain to approach and destabilize Mg2+:GDP via 
electrostatic force (Béraud-Dufour et al., 1998). Meanwhile, ARNO also induces a 
structural movement named “interswitch toggle” in Arf, preparing it for GTP binding 
(Renault et al., 2003). Notably, “interswitch toggle” requires the proximity of cellular 
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membranes as well, due to the amphipathic N-terminal helix of Arf and the myristoylated 
glycine residue on it (reviewed by Jackson and Casanova, 2000). In the inactive form, 
cytosolic Arf has N-terminal helix folded back with hydrophobic residues and myristoyl 
group buried, whereas in the presence of ARNO, Arf extends and inserts N-terminal helix 
into the lipid bilayer, rendering Arf tethered to the membrane, which in turn stabilizes this 
conformation by sequestering those hydrophobic moieties on N-terminal helix (Béraud-
Dufour et al., 1999; Goldberg, 1998). Therefore, this structural transition of “interswitch 
toggle” requires synergistic efforts from both ARNO and lipid bilayer.  
As the product of GDP-releasing phase, the nucleotide-free Sec7:Arf complex is relatively 
stable, in contrast to the Sec7:Arf:Mg2+:GDP intermediate. However, the latter is more 
informative and therefore motivates crystallization endeavor for capturing this key 
structure (Mossessova et al., 2003). To achieve this, brefeldin A (BFA), a fungal macrolide 
targeting Sec7:Arf complex, was introduced to structural studies. To be exact, BFA binds 
to the intermolecular interface between Sec7 and Arf to prohibit GDP release (Cherfils and 
Melancon, 2005). This abortive complex is like a snapshot of the dynamic exchange 
process, which allows structural basis of nucleotide release to be inspected. However, 
members of cytohesin family are BFA-insensitive, unlike other Arf GEFs such as BIG1 
(Brefeldin A-inhibited guanine nucleotide-exchange protein 1; reviewed by Kolanus, 
2007). Therefore, in a crystallization study of ARNO-Sec7:Arf1 complex, BFA-sensitizing 
mutations were introduced into ARNO-Sec7 to enable BFA binding (Renault et al., 2003).  
As can be seen in Figure 1.7, Sec7 consists of 10 α-helices (αA-J according to 
Mossessova et al., 1998), with αF-H forming a hydrophobic groove. The major Sec7-
contacting regions in Arf1 are switch 1 (residue 47-53) and switch 2 (residue 73-81), 
connected by a interswitch region spanning β2- and β3-strands (nomenclature following 
Goldberg, 1998). Rest of Arf1 structure is the core region, which is rigid compared to 
switch and interswitch regions. In this structure trapped by BFA, Arf1 is “straddling” Sec7, 
with one leg of switch 1 reaching into hydrophobic groove and the other leg of switch 2 
contacting αH-helix near the protein C-terminus. Hydrophobic residues I49, F51, I74 and 
L77 from both switch regions contribute to the docking of Arf1, so does an electrostatic 
attraction between K73 of Arf1 and D183 of Sec7 (Béraud-Dufour et al., 1998; Renault et 
al., 2003). Meanwhile, BFA resides at Sec7:Arf1 interface, caged in a hydrophobic cavity 
composed of residues from both proteins. Interestingly, glutamic finger (E156 at the 
beginning of αG-helix) is not close to Mg2+:GDP, with a distance of 8.2Å between terminal 
carboxyl carbon and Mg2+, which explains the inhibitory effect of BFA on nucleotide 
release. Notably, this BFA-captured structure shows merely the initial docking form of 
Arf1:Sec7. Another crystal of Arf1 in complex with ARNO-Sec7(E156K) in the absence of 
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BFA reveals the pre-dissociation form, in which “interswitch toggle” has already taken 
place (PDB ID: 1R8S; Renault et al., 2003). β2-/β3-strands and the connecting λ3 loop 
extrude from Arf1 core, impairing the binding site for N-terminal helix, so that it will shift 
away from the Arf1 and be ready for membrane insertion (Goldberg, 1998). More 
importantly, the hydrophobic cavity harboring BFA collapses in pre-dissociation form, 
which results in Arf1 core leaning towards Sec7 and thereby brings Mg2+:GDP closer to 
E156. Thus, docking form and pre-dissociation form, together with nucleotide-free form, 
represent three key steps in GDP-releasing procedure, in which Sec7 mediates structural 
rearrangement of Arf1 not just to expose the N-terminal helix for membrane anchoring, but 
also to drive GDP into closer proximity of glutamic finger before GDP being repelled and 
pushed off Arf1 (Renault et al., 2003).   
 
Figure 1.7 Crystal structure of ARNO-Sec7:Arf1:BFA complex. Full length Arf1 and ARNO-
Sec7(50-252) bearing BFA-sensitizing mutations (F190Y/A191S/S198D/P208M) are depicted as 
dark blue and dark green cartoons, respectively. Mg2+ ion is depicted as a red sphere, while 
glutamic finger and G3D are labeled and shown as sticks with carbons colored yellow and magenta, 
respectively. BFA is labeled and shown as sticks colored cyan, while αF-H are labeled. N-terminal 
helix, switch 1, interswitch and switch 2 are colored lemon green, orange, purple and yellow, 
respectively. G3D stands for guanosine-3’-monophosphate-5’-diphosphate, which is from E.coli 
overexpression of Arf1. Figure was prepared from PDB ID: 1R8Q (Renault et al., 2003) with 
PyMOL Molecular Graphics System. 
αH-helix
αF-helix
αG-helix
N-terminal helix
Interswitch
BFA E156
Switch 1
Switch 2
Mg2+
Introduction 
 
 15 
1.7 Activation of cytohesin 
Autoinhibition mechanism of cytohesins has been established, based on previous 
structural study of Grp1 (cytohesin-3), in which Sec7-PH linker and C-terminal helix are 
located in the proximity of hydrophobic groove of Sec7 and interfere with Arf binding. 
Additionally, deletion of PBR restores the cytohesin activities to different extents, 
suggesting its involvement in autoinhibition as well (DiNitto et al., 2007).  
Concerning the activation mechanism to relieve cytohesin autoinhibition, Arf6 has been 
unexpectedly reported as one candidate activator for cytohesin (Cohen et al., 2007). In 
contrast to Golgi-located Arf1, Arf6 is mainly distributed on plasma membrane and 
endoplasmic vesicle network, similar to cytohesins (D’Souza-Schorey and Chavrier, 
2006). This colocalization of Arf6 and cytohesins inspired the aforementioned cellular 
study, which proposes an activation mechanism that active GTP-bound Arf6 recruits 
ARNO or Grp1 to the plasma membrane and activates these GEFs in the presence of 
phosphoinositides. Instead of just being a substrate of cytohesins, Arf6 could also activate 
them by interacting with PH domain (Cohen et al., 2007). This allosteric activation 
mechanism was also confirmed in vitro via PIP2-containing liposomes (Stalder et al., 
2011).  
To unveil the structural basis of PH:Arf6 interaction, structure of Grp1-PH in complex with 
Arf6 was determined (Malaby et al., 2013). In this structure, Mg2+:GTP is bound to 
NΔ13Arf6(Q67L) which is constitutively active and lacking the N-terminal helix, while the 
head group of PIP3, i.e. IP4 (inositol 1,3,4,5-tetrakisphosphate), is bound to Grp1(247-
399) spanning Sec7-PH linker, PH domain and C-terminal helix. As can be seen in Figure 
1.8, interaction is primarily mediated by switch and interswitch regions from active Arf6 
and β3-/β4-/βi1-/βi2-strands from PH domain. Meanwhile, Sec7-PH linker and C-terminal 
helix flank the core interface by contacting switch 2 and switch1, respectively. Notably, β3-
/β4-/βi1-/βi2-strands of PH domain also interact with IP4. Therefore, structural changes in 
these regions, due to binding of highly charged IP4 (or PIP3), could affect Arf6 docking, 
which may explain the inositide-dependence of Arf6 allosteric activation (DiNitto et al., 
2007; Lietzke et al., 2000; Malaby et al., 2013). Interestingly, IP4 is on the same side of 
PH:Arf6 complex as the N-terminus of active Arf6, as shown in Figure 1.8 (B). Since PH is 
typically anchored to the membrane via phosphoinositides, while Arf GTPases via 
myristoylated N-terminal helix, this observation could explain how PH:Arf6 complex is 
oriented on the plasma membrane and thereby add more credit to the crystal structure.  
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Figure 1.8 Crystal structure of Arf6:PH complex. (B) is acquired from 90° rotation of (A) as 
indicated. NΔ13Arf6(Q67L) and PH-containing Grp1(247-399) are depicted as dark green and cyan 
cartoons, respectively. Mg2+ ion is depicted as a red sphere, while GTP and IP4 are shown as 
sticks with carbons colored yellow. Switch 1, interswitch and switch 2 of Arf6 are colored magenta; 
β3-/β4-/βi1-/βi2-strands of PH are colored dark blue; Sec7-PH linker and C-terminal helix are 
colored orange. In (B), plasma membrane is schematized as a grey box, while PIP3 and  N-
terminal helix are completed with dashed lines, with myristoyl group and acyl groups of PIP3 
highlighted as light red and light purple sticks, respectively. Nomenclature of secondary structures 
for both proteins follows Malaby et al., 2013. Figure was prepared from PDB ID: 4KAX (Malaby et 
al., 2013) with PyMOL Molecular Graphics System. 
Comparison of Arf6-bound PH with PH from autoinhibited Grp1 sheds light on the 
cytohesin activation mechanism (Malaby et al., 2013). As shown in Figure 1.9 (A), PH 
domains in both cases are essentially identical, whereas Sec7-PH linker and C-terminal 
helix shift drastically upon binding of active Arf6. With both autoinhibitory elements swung 
away from hydrophobic groove and catalytic glutamic finger, the activating role of GTP-
bound Arf6 could be partially explained. Yet with the bulky PH domain nearby, it is still 
unclear how Sec7 domain is reoriented to fully clear the hydrophobic groove for Arf 
substrates docking. One recent study, combining small-angle X-ray scattering and 
negative-stain EM, as well as rigid-body and ensemble analyses, reveals the structural 
flexibility of Grp1 hinge regions in solution, which are the residues connecting PH domain 
to Sec7-PH linker and C-terminal helix. According to this study, the swinging movement of 
C-terminal helix due to hinge flexibility brings it from autoinhibitory position to the proximity 
of PH domain, which leads to the free sampling of Sec7-PH linker in configuration space. 
Due to this linker flexibility, Sec7 is repositioned so that its catalytic site is entirely exposed 
and ready for accommodating substrate Arf (Malaby et al., 2018), as shown in Figure 1.9 
(B).  
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Figure 1.9 Activation mechanism of cytohesins. (A) Arf6:PH complex from Figure 1.8 and Grp1(63-
399) are overlaid based on superimposed PH domains. Grp1(63-399) carries K68A/H260Y 
mutations to achieve better diffraction without impairing exchange activity. Grp1(63-399) is 
depicted as dark blue cartoon with His-tag omitted, while Arf6 and PH from Arf6:PH complex are 
depicted as grey and green cartoons, respectively. Glutamic finger, IP4 and GTP are shown as 
sticks with carbons colored yellow. Sec7-PH linker and C-terminal helix are colored magenta in 
autoinhibited state, and orange in Arf6-bound state. Note the swinging movements of both 
elements. (B) MultiFoXS model of Arf6-activated Grp1 in complex with Arf1 substrate. Orientation 
of GDP-bound Arf1 is based on Sec7:Arf1 complex in PDB ID: 1R8S. Proteins are depicted as 
cartoons, while PIP3 on PH and myristoyl groups on Arf1/Arf6 are depicted as space-filling models. 
Figure (A) was prepared from PDB ID: 2R09 (DiNitto et al., 2007) and 4KAX with PyMOL Molecular 
Graphics System. Figure (B) was adapted from Malaby et al., 2018.  
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2 Research Aims 
According to the prevalent activation model of EGFR established by John Kuriyan lab, 
EGF binding triggers a chain of structural rearrangements which leads to allosteric 
activation of kinase domain (Arkhipov et al., 2013; Endres et al., 2013; Jura et al., 2009; 
Zhang et al., 2006). In this process, conformation equilibrium of EGFR kinase is shifted 
from inactive monomer/dimer towards active dimer (Jura et al., 2009). Yet the structural 
studies, which this activation model is based upon and supported by, have their own 
limitations. Firstly, the active (asymmetric) dimer structure was originally determined in 
crystallization studies (Stamos et al., 2002; Zhang et al., 2006), using proteins lacking key 
activating elements such as juxtamembrane latch and JM-A antiparallel helices. The same 
asymmetric dimer was also reported in catalytically dead EGFR kinase (Red Brewer et al., 
2009). This counter-intuitive observation could be caused by crystal packing effect due to 
high protein concentrations. Furthermore, the inactive (symmetric) dimer is derived from 
crystal structure of an EGFR mutant that purposefully impairs active dimer interface to 
force protein into its inactive form (Jura et al., 2009). Considering the central roles of 
asymmetric/symmetric dimers in EGFR activation model, it should be addressed first 
whether these two dimeric forms are actually present in dilute solution using unmutated 
EGFR, and if so, how frequently they are sampled by EGFR molecules. Secondly, both 
dimeric forms have been independently visualized via negative-stain electron microscopy 
(Lu et al., 2012; Mi et al., 2011). However, these images are “coarse-grained” and more 
evidence at molecular level is still urgently needed to support the activation model. As one 
of the emerging structural biology tools, electron paramagnetic resonance (EPR) promises 
protein sample analysis in solution or in detergent-/lipid-solubilized forms. Especially, 
pulsed electron-electron double resonance (PELDOR), one of the EPR methods, enables 
high-precision structural analysis of spin-labeled proteins by measuring interspin distance 
and deducing conformational dynamics from distance distribution. Therefore, the first part 
of this thesis aims at analyzing conformation distribution of dimeric EGFR kinases in 
solution and detergent/lipid micelles through collaboration with an EPR lab headed by 
Prof. Olav Schiemann.  
Another important aspect of EGFR activation is regulation by cytoplasmic modulators. 
EGFR activation is so important for cellular functions that apart from self-regulation via 
autoinhibition mechanism, it is also regulated by several cellular modulator proteins, which 
either interact directly with JM (calmodulin and TRAF4; Aifa et al., 2002; Cai et al., 2018; 
Martín-Nieto and Villalobo, 1998) or mimic binding mode of JM to the kinase core (Mig6; 
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Jura et al., 2009), underscoring the critical role of JM in EGFR regulation. Meanwhile, 
emerging evidence suggests ARNO (cytohesin-2) as a potential EGFR activator. One 
previous study has shown the correlation between ARNO overexpression and EGFR 
signaling in human colorectal cancer, with chemical inhibition of ARNO by SecinH3 
interfering with cell migration and proliferation (Pan et al., 2014). Another study shows that 
SecinH3 treatment effectively reduces EGFR signaling and proliferation of lung cancer 
cells (Bill et al., 2012). Connection between ARNO and EGFR in functional studies leads 
to the question of whether these two proteins directly interact, and if so, where the binding 
sites would be. Therefore, the second part of this thesis aims to investigate interaction 
between EGFR-ICD and ARNO, using established method of microscale thermophoresis 
(MST). Once interaction is confirmed, further MST assays will narrow down recognition 
motifs to protein domains or segments. Next, through collaboration with an NMR lab led 
by Dr. Manuel Etzkorn, EGFR-ICD:ARNO interaction shall be studied on amino acid level, 
using the domains identified by MST to characterize residues that are involved in this 
interaction.   
  
 
 
Results 
 
 20 
3 Results 
3.1 Conformation study of EGFR 
3.1.1 Purification and labeling of constructs for conformation study 
All the constructs investigated in this study are illustrated in Figure 3.1, together with a 
domain sketch of full length EGFR on the top. Most of the constructs were designed with 
MBP-tag at the N-terminus as a stabilizer during purification and labeling. Four among 
them contain EGFR-ICD truncated at the C-terminal border of kinase core (residue 998), 
which is the common practice for many structural and functional studies (Jura et al., 2009; 
Lu et al., 2012; Mi et al., 2008, 2011; Stamos et al., 2002; Zhang et al., 2006). Only one 
MBP-tagged construct, MBPT-ICD, includes complete intracellular domain of EGFR. 
Additionally, the SBP-tagged construct EGFRΔC contains entire extracellular and 
transmembrane domains, as well as intracellular domain truncated at residue 998, with 
SBP-tag fused to the C-terminus.   
 
 
Figure 3.1 Domain sketch of full length EGFR and all the constructs used in conformation study. 
Sequence numbering is based on human EGFR without signal peptide. Mutations in MBPT-
ICD998(I682Q) and MBPT-ICD998(V924R) are denoted by asterisks. In MBPT-
ICD998(4CSA/S744C), 4CSA mutations are indicated by vertical bars while S744C by hash sign.  
Proteins were expressed in Sf9 cells and large-scale purification coupled with labeling 
procedure was performed as described in Methods section. Briefly, MBP-tagged 
constructs were purified via amylose affinity chromatography, before labeling and size 
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exclusion chromatography (SEC). Collected fractions were pooled and concentrated, 
followed by buffer exchange into D2O-containing buffer in centrifugal filters. As for 
membrane protein EGFRΔC, all purification buffers were supplemented with TritonⓇ X-
100. Strep-TactinⓇ	affinity chromatography was performed first, with sample eluted in 
D2O-containing buffer, after which sample was concentrated and labeled. Labeling 
strategy for each construct will be introduced in following sections.  
Purified final products were visualized via SDS-PAGE and Coomassie staining. As shown 
in Figure 3.2, protein samples are relatively pure, except that MBPT-ICD is contaminated 
by ladder-patterned bands, which are probably protein degradation products. 
  
 
Figure 3.2 Final products of labeled protein for conformation study. 50 pmol of concentrated 
samples were resolved in SDS-PAGE. From left to right, the separating gels are 10%, 12.5%, 10% 
and 8%, respectively. S744C: MBPT-ICD998(4CSA/S744C), 998: MBPT-ICD998, WT: MBPT-ICD, 
VR: MBPT-ICD998(V924R), IQ: MBPT-ICD998(I682Q).  
3.1.2 Design and characterization of an MTSL-labeled construct 
In order to investigate EGFR-ICD conformation in solution, PELDOR spectroscopy was 
employed, which is one of the EPR spectroscopy methods. Briefly, PELDOR is a 
convenient, sensitive, low sample-consuming spectroscopic approach, in which 
diamagnetic protein is labeled by paramagnetic chemicals (also known as spin labels) and 
PELDOR acts as a molecular ruler to measure distance between paramagnetic centers. 
Acquired distance distribution is used to deduce information about protein conformation 
and structural dynamics. Depending on research interest, both intramolecular and 
intermolecular distances are measurable.  
Conventional protein PELDOR study utilizes nitroxide spin label such as MTSL (S-(1-oxyl-
2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl methanesulfonothioate), and the 
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labeling process relies upon reactivity of thiosulfate ester towards sulfhydryl group in the 
side chain of cysteine (Figure 3.3).  
 
 
                          
Figure 3.3 Reaction of MTSL with a cysteine residue of the protein 
However, native cysteines of EGFR are unsuited for the labeling, because they do not 
meet the candidate criteria described below. By site-directed mutagenesis, solvent-
exposed endogenous cysteines were substituted with either serine or alanine depending 
on hydrophobicity around the residue, after which new cysteine was introduced at proper 
amino acid site for MTSL labeling. In the first round of mutation, 4CSA combination 
(C751S/C757A/C773S/C915A) was designed. According to crystal structures of active 
and inactive kinase domain of EGFR (PDB ID: 2GS6 and 3GT8), native cysteines C794 
and C926 face inside of the helix bundle in C-lobe, and therefore remain unmutated since 
they are not accessible to MTSL. In the second round of mutation, only one cysteine was 
introduced into ICD aimed at measuring intermolecular distance, considering that 
research goal is to study EGFR-ICD conformation, or to be exact, the distribution of the 
different possible conformations of dimeric EGFR in solution. Proper amino acid site for 
the new cysteine was selected based on several criteria. First, candidate locations have to 
be solvent-exposed in both asymmetric and symmetric ICD dimers. In this thesis project, 
structural models of both dimers are taken from a previous study (Arkhipov et al., 2013), in 
which dimeric near-full-length EGFR in lipid bilayer was simulated, with both kinase dimer 
models being based on aforementioned structures (PDB ID: 2GS6 and 3GT8). Second, in 
both asymmetric and symmetric dimers, distances between candidate locations should be 
within optimal PELDOR measurement range, which is approximately 18 to 80Å (reviewed 
by Jeschke and Polyhach, 2007; reviewed by Schiemann and Prisner, 2007; reviewed by 
Tsvetkov et al., 2008). Third, aforementioned distances should be different between 
asymmetric and symmetric dimers, so that these two conformations are distinguishable 
via PELDOR.   
Candidate construct MBPT-ICD998(4CSA/S744C), which meets all the selection criteria, 
was expressed, purified and labeled as documented in Methods section, with final sample 
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visualized via SDS-PAGE (Figure 3.2). Before starting PELDOR measurement, 
autophosphorylation assay was also performed to examine protein activity. The 
intracellular domain (ICD) of EGFR harbors at its core a kinase domain which, upon 
activation, transfers the γ-phosphate group of ATP to one of the tyrosines in C-terminal 
tail. Thus, phosphorylation of tyrosine can be utilized as indicator of kinase activity. The 
EGFR autophosphorylation has such physiological significance that plenty of antibodies 
have been commercialized for immunodetection, targeting generic or specific 
phosphotyrosine. Here an antibody targeting phosphotyrosine 992 was utilized in western 
blot. As shown in Figure 3.4, MBPT-ICD998(4CSA/S744C) is unfortunately inactive, with 
no increased phosphorylation at 1 or 3min. The loss of activity could be due to multiple 
mutations or MTSL labeling. Without evidence to prove that protein is still functional, this 
study cannot proceed to PELDOR measurement. New labeling strategy is needed.  
 
Figure 3.4 Autophosphorylation assay of MTSL-labeled MBPT-ICD998(4CSA/S744C). Detailed 
assay procedure is provided in Methods section. 1.4 pmol of phosphorylated samples stopped at 
indicated time points were visualized via western blot. Total EGFR intensities were detected by 
anti-MBP antibody on MBP blot, and phosphorylated Y992 by anti-phosphotyrosine antibody on 
pY992 blot. 998: MBPT-ICD998, S744C: MBPT-ICD998(4CSA/S744C) labeled by MTSL.  
3.1.3 Design and characterization of PDsl 
3.1.3.1 Introduction of IDSL and PDsl 
The following sections will focus on a new protein labeling strategy, named inhibitor-
directed spin labeling (IDSL). This strategy takes advantage of the excellent binding 
affinity of certain protein inhibitors, which are covalently attached to spin label moieties to 
suit measurement purposes. Once protein is bound to such modified inhibitor, it becomes 
spin-labeled. One major benefit of this method is that no mutation is required, which 
means protein structure information is extracted under more natural conditions. Some 
inhibitors even covalently bind to the target protein, so purification steps after labeling will 
not wash them off. One such inhibitor, PD168393 developed by Parke, Davis & Co. (now 
part of Pfizer) was used in this study and it targets EGFR kinase domain. After occupying 
0 1 3 0 1 3 min
pY992
MBP
S744C998
kDa
100
70
100
70
Results 
 
 24 
ATP-binding cleft, PD168393 forms a covalent bond with EGFR via Michael addition 
between its acrylamide warhead and sulfhydryl group of C773 nearby (Figure 3.5).  
IC50 of PD168393 from publications is concluded as either < 1nM (Blair et al., 2007) or 
0.08nM (Michalczyk et al., 2008), which is convenient for the labeling process. In a 
previous study, PD168393 was coupled to NBD fluorophore via PEG at C7 of the 
quinazoline backbone, and was successfully applied to cellular study as a fluorescence 
probe. Additionally, ICD(672-998) was already cocrystallized with PD168393, which 
provides useful binding detail of this inhibitor on ATP-binding site (PDB ID: 2J5F; Blair et 
al., 2007). Furthermore, one molecule of EGFR-ICD binds to only one copy of PD168393, 
which is especially suitable for conformation studies on the EGFR dimer.    
 
 
                         
Figure 3.5 Reaction of PD168393 with cysteine residue in the protein 
 
Figure 3.6 Structure of PD168393sl  
In the current PELDOR study, an analogous strategy was adopted for probe design, in 
which PD168393 was linked to nitroxide spin label at C7 of the quinazoline backbone. A 
linker shorter than PEG, ethanolamine, was used since it increases steric rigidity between 
the spin label moiety and inhibitor moiety, thus leading to narrower peaks in distance 
distribution graph. This EPR probe was named PD168393sl (PDsl for short), with structure 
shown in Figure 3.6. Based on ICD-PD168393 cocrystal structure (PDB ID: 2J5F) and 
other simulation models (Arkhipov et al., 2013), spin-spin distances in both asymmetric 
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and symmetric EGFR dimers were predicted using a PyMOL plugin mtsslWizard 
(Hagelueken et al., 2012), and they lie within PELDOR measurement range. More details 
about the calculation will be provided in section 3.1.4. The probe was kindly synthesized 
and characterized in detail by Jeffrey Hannam (Yin et al., 2017). 
3.1.3.2 Activity assay comparing PD168393 & PDsl 
Since PD168393 is an ATP-competitive kinase inhibitor, a natural approach to confirm 
protein labeling is to visualize inhibited autophosphorylation of EGFR via western blot. 
Also, it is unclear whether attached spin label on PDsl influences its inhibitory effect, and 
this issue can be resolved via the same method. 
Autophosphorylation assay and western blot were performed as described in Methods 
section. For each sample at indicated time point, the ratio between phosphorylation and 
EGFR intensities was calculated, after which these ratios were normalized by the value at 
0 min, giving relative phosphorylation (rel. phos.). As shown in Figure 3.7, PD168393 and 
PDsl inhibit ICD autophosphorylation to the same extent, with approximately 6.7% relative 
phosphorylation intensity left, compared to unlabeled protein at both 1 and 3min. To 
conclude, PDsl effectively binds to EGFR-ICD, and attached spin label has no influence 
over its binding.  
 
Figure 3.7 Autophosphorylation assay comparing PD168393- and PDsl-labeled MBPT-ICD998. 
Detailed assay procedure is provided in Methods section. 1.4 pmol of phosphorylated samples 
stopped at indicated time points were visualized via western blot. Total EGFR intensities were 
detected by anti-MBP antibody on MBP blot, and phosphorylated Y992 by anti-phosphotyrosine 
antibody on pY992 blot. “-”: unlabeled protein, “+PD”: PD168393-labeled, “+PDsl”: PDsl-labeled, 
rel.phos.: relative phosphorylation.  
3.1.3.3 Activity assay of PDsl-labeled constructs 
The purpose of this section is to fully examine PDsl labeling of all the constructs in EPR 
project, using the same methodology as in previous section, i.e. autophosphorylation 
assay.  
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Figure 3.8 Autophosphorylation assay of PDsl-labeled constructs. Detailed assay procedure is 
provided in Methods section. 1.5 pmol of phosphorylated samples stopped at indicated time points 
were visualized via western blot. Total EGFR intensities were detected by anti-MBP antibody on 
MBP blot, and phosphorylated Y992 by anti-phosphotyrosine antibody on pY992 blot. “-”: unlabeled 
protein, “+PDsl”: PDsl-labeled protein, WT and *: MBPT-ICD, 998 and >: MBPT-ICD998, rel.phos.: 
relative phosphorylation.  
 
Figure 3.9 Autophosphorylation assay of PDsl-labeled constructs. Detailed assay procedure is 
provided in Methods section. 1.5 pmol of phosphorylated samples stopped at indicated time points 
were visualized via western blot. Total EGFR intensities were detected by anti-MBP antibody on 
MBP blot, and phosphorylated Y992 by anti-phosphotyrosine antibody on pY992 blot. “-”: unlabeled 
protein, “+PDsl”: PDsl-labeled protein, VR: MBPT-ICD998(V924R), IQ: MBPT-ICD998(I682Q), 
rel.phos.: relative phosphorylation.  
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In Figure 3.8, assay results for MBPT-ICD and MBPT-ICD998 were visualized via western 
blot, with relative phosphorylation intensities calculated and denoted under sample lanes. 
One can clearly see that PDsl inhibits autophosphorylation of these two constructs. 
Notably, contaminations in MBPT-ICD, visualized by SDS-PAGE in Figure 3.2, are 
recognized by anti-MBP antibody. In conjunction with the fact that they were copurified 
based on the binding of N-terminal MBP-tag to amylose resin, these additional bands 
probably represent degraded proteins losing parts of EGFR C-terminal tail.  
In previous studies, V924R and I682Q mutations were introduced at asymmetric ICD 
dimer interface on the C-lobe and N-lobe side, respectively (Jura et al., 2009; Zhang et al., 
2006). Since asymmetric dimer is associated with active kinase conformation (reviewed 
by Bose and Zhang, 2009), either mutation alone impairs phosphorylation activity of 
EGFR by hindering asymmetric dimer formation. However, V924R still retains an intact N-
lobe and I682Q an intact C-lobe. When these two combine to form a complete asymmetric 
dimer interface, kinase activity is partially restored. In the current study, MBPT-
ICD998(V924R) and MBPT-ICD998(I682Q) were designed for EPR investigation. Judged 
by relative phosphorylation in Figure 3.9, both constructs show certain level of kinase 
activity, and activity increases after combining them in “VR+IQ”. However, the contrast 
between activities of “VR+IQ” and “VR” or “IQ” is less pronounced, compared to previous 
studies (Jura et al., 2009; Zhang et al., 2006). This could be explained by the different 
methodologies adopted in activity assays, i.e. western blot of autophosphorylation at Y992 
here vs. enzyme-coupled spectrophotometric assay of substrate phosphorylation in 
aforementioned publications. Nevertheless, inhibited autophosphorylation is observed in 
PDsl-treated group (Figure 3.9), which indicates proteins being labeled. Noteworthy, 
autophosphorylation assay is not intended to quantitatively measure labeling efficiency of 
PDsl. To achieve that, a more direct approach named spin counting was adopted (see 
section 3.1.4).    
Another construct included in EPR study is EGFRΔC, which contains extracellular, 
transmembrane and intracellular domain truncated at G998, as well as SBP-tag fused at 
C-terminus. Large-scale purification and labeling process is documented in Methods 
section. For autophosphorylation assay, unlabeled EGFRΔC was pre-incubated with PDsl 
and EGF in 1: 1: 1.2 molar ratio on ice for 10min. As controls, EGF was replaced by equal 
volume of water (-EGF), or PDsl was replaced by equal volume of DMSO (-). Reaction 
was initiated by adding 1mM ATP and 5mM MgCl2, and terminated by adding SDS-PAGE 
loading buffer with 25mM EDTA. Samples were analyzed via western blot, which shows 
clearly that PDsl blocks EGF-stimulated as well as basal EGF-independent kinase activity 
(Figure 3.10). Thus EGFRΔC is also effectively labeled by PDsl.  
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Figure 3.10 Autophosphorylation assay of PDsl-labeled EGFRΔC. Detailed assay procedure is 
provided in Methods section. 0.375 pmol of phosphorylated samples stopped at indicated time 
points were visualized via western blot. Total EGFR intensities were detected by Streptavidin on 
SBP blot, and phosphorylated Y992 by anti-phosphotyrosine antibody on pY992 blot. “-”: unlabeled 
protein, “+PDsl”: PDsl-labeled protein.   
 
Figure 3.11 Autophosphorylation assay studying effect of deuterated ethylene glycol. Detailed 
assay procedure is provided in Methods section. 1.4 pmol of phosphorylated samples stopped at 
indicated time points were visualized via western blot. Total EGFR intensities were detected by 
anti-MBP antibody on MBP blot, and phosphorylated Y992 by anti-phosphotyrosine antibody on 
pY992 blot.  
Since final PELDOR samples should be heavily supplemented with deuterated ethylene 
glycol (50%), kinase activity under such conditions needs to be investigated. (The reason 
for the supplementation will be explained in Section 3.1.4). As shown in Figure 3.11, 
sample with 50% deuterated ethylene glycol (+) shows slightly less phosphorylation than 
sample without deuterated ethylene glycol (-), which could be explained by increased 
viscosity and reduced phosphorylation rate by ethylene glycol. As kinase activity is not 
drastically reduced in 50% ethylene glycol, this study can proceed without major concern 
regarding a potential denaturing effect of ethylene glycol.  
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3.1.4 EPR measurement of PDsl-labeled constructs 
3.1.4.1 CW-EPR for spin counting 
The mission of this section is to determine labeling efficiency, which is defined as the ratio 
of protein-bound spin concentration to protein concentration. Labeling efficiency reflects 
the extent to which protein is spin-labeled. Since underlabeling hinders subsequent 
PELDOR data interpretation, it is necessary to confirm the sufficient labeling of all 
samples before PELDOR measurement.  
 
Figure 3.12 Labeling efficiencies of MBP-tagged constructs by PDsl. Horizontal axis represents the 
labeling efficiency as the ratio between spin and protein concentrations. Each sample is presented 
as a color-coded horizontal bar with length equal to its marked labeling efficiency. All samples are 
spin-counted in the absence of ethylene glycol. WT: MBPT-ICD, 998: MBPT-ICD998, VR: MBPT-
ICD998(V924R), IQ: MBPT-ICD998(I682Q).   
Spin concentrations were determined via spin counting, while protein concentrations were 
measured via NanoDrop beforehand. To count the spin, X band continuous wave EPR 
(CW-EPR) and subsequent analysis were performed by Gregor Hagelüken. Double 
integrals of the field sweep spectra of labeled samples were compared with an internal 
reference of the spectrometer in order to derive the spin concentrations. Due to distinct 
labeling procedure EGFRΔC sample contains free spin, which means counted spin is not 
exclusively protein-bound spin. Therefore, labeling efficiency of EGFRΔC was not 
determined. For other constructs, ratios between spin and protein concentrations are 
illustrated in Figure 3.12 as labeling efficiencies. As can be seen, labeling efficiencies of 
“VR” and “IQ” are close to 1.1, yet for “WT” and “998” they are close to 0.85. Considering 
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the +/- 10-20% accuracy of spin counting, the variation between values is acceptable. 
Therefore, samples are considered sufficiently labeled, and ready for PELDOR 
measurement.  
3.1.4.2 PELDOR for conformation study 
After evaluating the labeling efficiency of PDsl, Q-band PELDOR measurements of spin-
labeled proteins were performed by Gregor Hagelüken, in order to explore the dimer 
distribution of EGFR. Samples were prepared as described in Methods section, and 
measured in PELDOR at the same protein concentration. Noteworthy, all samples were 
exchanged into D2O-containing buffer to reduce proton spin diffusion and achieve longer 
T2 relaxation time. Furthermore, labeled samples were mixed with deuterated ethylene 
glycol in 1:1 volume ratio before being flash-frozen in Q band PELDOR tubes. Without 
ethylene glycol, water would form ice crystal during freezing process and expel out 
labeled protein, which causes spin clustering and shorter T2 relaxation times. In PELDOR, 
longer T2 relaxation time is generally desired for measuring long spin-spin distance and 
achieving high signal noise ratio.  
 
Figure 3.13 Simulation models of asymmetric and symmetric EGFR dimers (Arkhipov et al., 2013). 
Both dimer conformations are depicted as cartoon, with either monomer colored green or cyan. 
The grey horizontal bar represents plasma membrane, while magenta and yellow cartoons 
represent EGF peptides bound to extracellular domains. Modeled spin labels are denoted by dark 
blue spheres, and interspin distances are presented as red lines with labeled values. This figure 
was prepared by Gregor Hagelüken using PyMOL Molecular Graphics System. 
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At first, based on ICD-PD168393 cocrystal structure (PDB ID: 2J5F) and simulation 
models (Arkhipov et al., 2013), spin-spin distances in symmetric and asymmetric dimers 
were calculated by mtsslWizard to be 30Å and 65Å, respectively (Figure 3.13).  
Thereafter, MBP-tagged constructs containing EGFR intracellular domain were measured 
in PELDOR. The data were processed using DeerAnalysis2016 Software (Jeschke et al., 
2006). Briefly, the background was removed by dividing signal by a stretched exponential 
function and the spin-spin dipolar distances were extracted by Tikhonov regularization.  
Surprisingly, both MBPT-ICD and MBPT-ICD998 show single well-shaped peak around 
63Å in distance distribution, close to the value for asymmetric dimer conformation. No 
discernible peak can be found at other distances, especially the one corresponding to 
symmetric dimer (Figure 3.15). To identify the nature of this single peak, V924R and 
I682Q mutations were introduced individually, so that if 63Å peak disappears in their 
separate PELDOR measurements and reappears when two mutants are combined, it 
would confirm that the peak indeed results from asymmetric dimer. However, “VR” and 
“IQ” still result in the same PELDOR distance peak centered around 63Å (Figure 3.15). 
Also, “VR” contains three bumps at smaller distances, probably due to lack of pronounced 
oscillation pattern in its time trace (Figure 3.14 & 3.15).   
 
Figure 3.14 Corrected PELDOR time traces of MBP-tagged constructs. Each sample is at 13μM 
concentration, except “VR + IQ” (7μM+ 7μM). Original time traces were divided by background 
functions (in the form of exponential decay) to acquire corrected time trace. V(T) is integral echo 
intensity normalized at time zero and horizontal axis is spin-spin dipolar evolution time. Modulation 
depth Δ in each measurement is marked as a short bar on the vertical axis at value of 1- Δ. Time 
trace and modulation depth bar for each construct are color-coded. Uncorrected time traces and 
background functions are plotted in Appendix Figure S1. WT: MBPT-ICD, 998: MBPT-ICD998, VR: 
MBPT-ICD998(V924R), IQ: MBPT-ICD998(I682Q).  
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Figure 3.15 Distance distributions of MBP-tagged constructs. Horizontal axis represents spin-spin 
distance in nanometer, while P(r) on the vertical axis is distance distribution function. Curves of all 
constructs are color-coded and superimposed with simulated asymmetric or symmetric dimer 
distance distribution (grey peaks). WT: MBPT-ICD, 998: MBPT-ICD998, VR: MBPT-
ICD998(V924R), IQ: MBPT-ICD998(I682Q).  
 
Figure 3.16 Illustration of modulation depth of a corrected PELDOR time trace from simulation. 
Vertical axis V(Τ) represents normalized integral echo intensity, while horizontal axis represents 
dipolar evolution time. Vertical double-headed arrow denotes the modulation depth Δ of the dipolar 
oscillation pattern. Corresponding distance distribution is shown in the inset. Figure is adapted from 
Jeschke and Polyhach, 2007.  
Another perspective for data interpretation in Figure 3.14 is modulation depth comparison. 
Modulation depth Δ of a PELDOR time trace is described as difference between V(T)max 
(1.0 at T = 0) and V(T) at the time point when spin-spin dipolar oscillation almost dies out, 
as illustrated in Figure 3.16. Modulation depth is correlated with the number of coupled 
spins. The more spins are coupled, the more deeply time traces are modulated. In Figure 
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3.14, modulation depth for each individual construct is marked on vertical axis at the value 
of 1- Δ. Although “VR” and “IQ” both show peaks centered around the same distance as 
unmutated MBPT-ICD998 does (63Å), they have smaller modulation depths (4.8% and 
15.5%, respectively) compared to MBPT-ICD998 (28.1%). Since data in previous section 
indicate that labeling efficiencies of “VR” and “IQ” are close to each other and slightly 
higher than MBPT-ICD998, it rules out the possibility that shallower modulations in “VR” 
and “IQ” are caused by underlabeling. Instead, data can be explained by disruption of 
asymmetric dimer interface and lack of symmetric dimerization in V924R and I682Q 
samples. These two mutations perhaps push EGFR conformation equilibrium from 
asymmetric dimer only towards monomeric form, not towards symmetric dimer. Thus 
fewer spins are coupled, resulting in reduced modulation depth of the time traces. This 
explanation is corroborated by PELDOR measurement of “VR+IQ”, where mixture of the 
two mutants shows deeper modulation (23.7%) than either of them alone. As elaborated 
in 3.1.3.3, V924R and I682Q mixture could form asymmetric “heterodimers”, and thereby 
partially regains the deep modulation. Yet still the modulation is not fully restored to the 
depth of unmutated MBPT-ICD998, because there is only 50% chance that a V924R 
molecule encounters an I682Q molecule with which it can form an asymmetric dimer, 
whereas every two MBPT-ICD998 molecules are able to pair up as an asymmetric dimer. 
Additionally, since orientation selectivity of the spin label could also cause differences in 
modulation depths, PELDOR time traces at different frequency offsets were recorded to 
exclude this possibility (Yin et al., 2017). 
 
Figure 3.17 PELDOR modulation depths of MBP-tagged constructs. Each bar is color-coded same 
as in Figure 3.14, with its height equal to modulation depth. Values of modulation depth Δ are 
labeled as percentage on the bars. WT: MBPT-ICD, 998: MBPT-ICD998, VR: MBPT-
ICD998(V924R), IQ: MBPT-ICD998(I682Q). Each bar represents a single measurement. 
Another interesting comparison lies between MBPT-ICD998 and MBPT-ICD, where the 
latter shows reduced modulation depth (18.9%) compared to the former (28.1%). It is also 
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observed that labeling efficiencies of these two constructs are similar, with MBPT-ICD 
slightly higher than MBPT-ICD998 (see previous section), thus excluding underlabeling as 
the reason for shallower modulation. According to other studies, C-terminal tail exerts 
autoinhibitory influence over the EGFR kinase activity by pushing conformation 
equilibrium away from asymmetric dimer (Bublil et al., 2010; Jura et al., 2009). Therefore, 
reduced modulation depth of MBPT-ICD could be explained by less asymmetric dimer 
formation because of C-terminal tail autoinhibition, although this explanation requires 
further experimental confirmation. Additionally, each construct was purified, spin-labeled 
and measured in PELDOR at least one more time, with consistent modulation depth data 
summarized in Figure 3.17.  
So far, all of the MBP-tagged constructs have been measured in PELDOR, mostly with 
distance distribution showing a single peak centered around 63Å, which is assigned to 
ICD asymmetric dimer after modulation depth analysis. However, it is unclear whether the 
large MBP-tag (40kDa) influences spin-spin distance, or whether measurement of 
intracellular domain alone reflects the conformation distribution of EGFR as a 
transmembrane protein. To answer these questions, EGFRΔC construct with two distinct 
features was designed. First, MBP-tag is replaced by a small SBP-tag (4.3kDa) fused at 
C-terminus. Second, as mentioned in section 3.1.1, this construct contains almost full 
length EGFR (residue 1-998) with only C-terminal tail partly missing. During purification, 
EGFRΔC was solubilized by TritonⓇ X-100 micelles. Since TritonⓇ X-100 interferes with 
protein concentration measurement at 280nm on NanoDrop, EGFRΔC concentration was 
determined via western blot, by comparing its band intensity with those of serially diluted 
EGFR-ICD998(K721M), of which the concentration can be measured via 280nm 
absorption. Thereafter, EGFRΔC was labeled by mixing it with PDsl at molar ratio of 1:1.1, 
immediately followed by ethylene glycol supplementation and flash freezing. Since there 
was no gel filtration step to remove unbound PDsl, labeling efficiency could not be 
correctly calculated from measured spin concentration. Also, free spins reduce modulation 
depth of PELDOR trace, so no conclusion could be drawn from modulation depth 
comparison. Therefore, data interpretation for EGFRΔC is confined to analyzing extracted 
distance distribution.  
As can be seen in Figure 3.18, PELDOR trace of EGFRΔC shares a similar oscillation 
pattern with MBPT-ICD998 trace. Accordingly, its interspin distance distribution features 
the same pattern as MBPT-ICD998 does, i.e. the peak around 63Å	(Figure 3.19). 
Therefore, labeled SBP-tagged EGFRΔC also stays in asymmetric dimer conformation 
under the conditions of TritonⓇ X-100 micelle, so the conclusion on conformational 
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distribution of MBP-tagged EGFR-ICD constructs can be extended to larger 
transmembrane EGFR construct. 
 
Figure 3.18 Corrected PELDOR time traces of EGFRΔC and MBPT-ICD998. Sample 
concentration is 13μM. “998” trace is taken from Figure 3.14 as a reference. V(T) is integral echo 
intensity normalized at time zero and horizontal axis is spin-spin dipolar evolution time. Time trace 
for each construct is color-coded. Uncorrected time traces and background functions are plotted in 
Appendix Figure S1. 998: MBPT-ICD998.  
 
Figure 3.19 Distance distributions of EGFRΔC and MBPT-ICD998. Horizontal axis represents 
spin-spin distance in nanometer, while P(r) on the vertical axis is distance distribution function. 
Peaks centered around 63Å are scaled to the same height for comparison. Curves of both 
constructs are color-coded and superimposed with simulated asymmetric or symmetric dimer 
distance distribution (grey peaks). 998: MBPT-ICD998.  
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3.1.5 Analytical gel filtration 
As mentioned in previous section, the shallower modulation of “VR” and “IQ” PELDOR 
traces can be explained by the shift of conformational equilibrium from asymmetric dimer 
to monomer. The goal of this section is to compare oligomeric states cross different 
PELDOR samples via analytical gel filtration, thereby further corroborating that 
explanation. 
 
Figure 3.20 Analytical gel filtration of MBP-tagged constructs. Vertical axis represents relative 
absorbance at 280nm. PELDOR samples were retrieved and injected into SuperdexTM 200 10/300 
GL column. The chromatogram of each construct is rescaled with maximum absorbance at 1.0, 
and color-coded in the same way as in Figure 3.14. Protein standards from Gel Filtration Marker Kit 
MWGF1000 were injected separately as references, and the elution volume for maximum 
absorbance of each standard is denoted in the plot as a grey vertical line, with corresponding 
molecular weight labeled on the top. 998: MBPT-ICD998, VR: MBPT-ICD998(V924R), IQ: MBPT-
ICD998(I682Q). 
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Analytical gel filtration of four PELDOR samples, i.e. MBPT-ICD998, “VR”, “IQ” and 
“VR+IQ”, was performed by Fraser Duthie. First, four gel filtration markers were injected 
successively into pre-equilibrated SuperdexTM 200 10/300 GL column. Thereafter, 
PELDOR samples were retrieved from Q-band tubes and injected separately into the 
same column. Chromatograms were then compared between PELDOR samples and 
protein markers.  
In Figure 3.20, four protein markers are presented as grey vertical lines in each graph. 
The chromatogram of every PELDOR sample contains single major peak, with maximum 
absorbance passing between “150kDa” and “66kDa” markers. Since theoretical mass 
differences among these constructs are negligible, it is safe to assume that monomeric 
state is 82kDa and dimeric state is 164kDa for all constructs. The peak of “998” is broad 
with a long tail after the maximum absorbance around “150kDa”, suggesting a majority of 
dimeric state mixed with monomers. On the other hand, “VR” and “IQ” show more focused 
peaks close to “66kDa”, whereas “VR+IQ” lies between “998” and “VR”/ “IQ”. Therefore, 
both “VR” and “IQ” stay more in the monomeric state compared to “998”, while “VR+IQ” 
partially restores the dimeric state of “998”, which fits well with the conclusion from 
PELDOR. Since the elution volume gap between “150kDa” and “66kDa” is narrow 
(1.3mL), monomeric and dimeric states cannot be resolved as separate peaks in 
chromatograms, which explains why “VR+IQ” shows only one peak.  
To conclude the EGFR conformation study, a new spin labeling strategy, i.e. inhibitor-
directed spin labeling (IDSL) has been developed, and it was successfully applied to 
EGFR conformation study by designing one such inhibitor-based spin label PDsl for 
interspin distance determination. PELDOR measurements of MBP-tagged ICD and SBP-
tagged EGFRΔC show single peak in distance distribution which corresponds to 
asymmetric dimer of kinase domain. V924R and I682Q mutations shift the conformational 
equilibrium from asymmetric dimer towards monomer while no symmetric dimer is 
observed. Analytical gel filtration further corroborates the equilibrium shift by examining 
the oligomeric states of PELDOR samples.  
3.2 Protein interaction study of EGFR 
3.2.1 Purification of constructs for interaction study 
Shown below is an overlook of constructs involved in the protein interaction study (Figure 
3.21). All constructs are based on human sequences. As protein interactions of EGFR 
intracellular domain are studied, all EGFR constructs contain only the intracellular domain 
or parts thereof.  
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Figure 3.21 Domain sketch of all the constructs used in interaction study. Sequence numbering is 
based on human proteins. Mutations in Sec7(4A) are indicated by vertical bars. JMsc: scrambled 
JM.  
Details about plasmids, recombinant protein expression and purification procedures can 
be found in Materials and methods. Regarding purification, briefly, proteins were purified 
at first via different affinity chromatography methods depending on the attached tags. 
Eluted samples were subsequently buffer-exchanged into desalting buffer, followed by 
TEV protease cleavage. TEV-treated samples were incubated with affinity resin again to 
remove the free affinity tags and uncleaved protein, after which size exclusion 
chromatography was performed to remove impurities and protein aggregate. Samples 
from target peak were collected and if necessary, concentrated with centrifugal filters to 
reach the concentration as required by interaction study.   
It is worth mentioning that ICDΔJM27 construct could only be obtained in sufficient 
amounts, when the first 27 amino acids of JM were still present during expression. 
Therefore, a TEV cleavage site was inserted between amino acids 27 and 28 of the JM 
segment and the fragment containing first 27 amino acids was cut off by TEV during 
purification, leading to final product of ICDΔJM27. 
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Purified protein samples were visualized via SDS-PAGE and Coomassie staining. As can 
be seen in Figure 3.22, final products are very pure except that ARNOΔPBR is slightly 
contaminated by multiple residual protein bands. Moreover, JM and scrambled JM (noted 
as JMsc) show less focused bands in SDS-PAGE, probably due to smaller sizes. To sum 
up, acquired protein samples are fit for the downstream analyses.  
 
 
 
Figure 3.22 Final products of EGFR, ARNO and calmodulin constructs. 50 pmol of concentrated 
samples were visualized via SDS-PAGE (200 pmol for JM and JMsc). From left to right, the 
separating gels are 8%, 15% and 12.5%, respectively. Purification detail is in Methods section. 
3.2.2 Quality control of purified constructs 
Once protein purification is completed, it would be necessary to perform certain activity 
assay to examine whether protein functions are still intact. For EGFR, 
autophosphorylation assay was applied to check kinase activity. As for ARNO-Sec7, it 
functions as a guanine nucleotide exchange factor on ARF GTPases, so various ARNO-
related constructs were tested in guanine nucleotide exchange assay to compare 
aforementioned activities between constructs.  
3.2.2.1 Autophosphorylation assay 
Autophosphorylation assay of ICD and ICDΔJM27 was conducted as described in 
Methods section, followed by western blot with antibody against generic phosphotyrosine 
and antibody recognizing cytoplasmic domain of EGFR. Protein bands were visualized by 
corresponding secondary antibodies conjugated to fluorophores, before being scanned 
and quantified by Image StudioTM software. Phosphorylation intensities were normalized 
against total EGFR intensities for each time-point. Such normalized phosphorylation was 
250
130
100
70
55
35
25
kDa
IC
D
IC
DΔ
JM
27
250
130
100
70
55
35
25
15
10
kDa Se
c7
Se
c7
(4A
)
Ca
lm
od
uli
n
JM JM
sc
AR
NO
AR
NO
ΔP
BR
AR
NO
-P
H
250
130
100
70
55
35
25
15
10
kDa
Results 
 
 40 
used to further calculate relative phosphorylation (rel. phos.) at 1min and 3min, with 
values at 0 min set as 1. In Figure 3.23, ICDΔJM27, lacking major part of JM, shows much 
less phosphorylation than ICD. At 1min, only 12% of relative phosphorylation was left in 
ICDΔJM27 compared to ICD, while at 3min, 15%. The dramatic drop of activity can be 
attributed to the deletion of first 27 amino acids of JM segment, which plays a critical role 
in dimerization and activation of EGFR kinase domain. So far the phosphorylation result is 
well in line with canonical EGFR activation model, supporting the usage of these two 
constructs for further interaction studies.  
 
 
 
Figure 3.23 Autophosphorylation assay of ICD constructs analyzed by western blot. Assay was 
performed with 100nM ICD and ICDΔJM27. Total EGFR intensities were detected by anti-EGFR 
antibody on the left (EGFR blot) while phosphorylated EGFR by anti-phosphotyrosine antibody on 
the right (pY blot). Relative phosphorylation (rel. phos.) is marked under each lane of the pY blot.  
3.2.2.2 Guanine nucleotide exchange assay 
Sec7 domain functions as GEF on Arf GTPase such as Arf1, which is exploited in activity 
assay of Sec7-containing constructs. The common guanine nucleotide exchange assays 
use radioactive, fluorescent-labeled nucleotide, non-hydrolysable nucleotide analog or just 
plain GTP/GDP pair (Eberth and Ahmadian, 2009; Randazzo et al., 2013; Stalder et al., 
2011). For Sec7:Arf1 nucleotide exchange, an assay system with GTP/GDP pair has been 
well established in the lab, which monitors intrinsic tryptophan fluorescence instead of 
radioactivity or external fluorescence. In addition, it is unnecessary to use non-
hydrolysable nucleotide such as GppNHp due to the low inherent GTPase activity of His-
NΔ17Arf1, a variant of Arf1 truncated for better solubility. 
The basis of the tryptophan fluorescence assay is that the structural switch of GTPase 
from GDP-bound state to GTP-bound state, and the concomitant microenvironment 
change around tryptophan residue(s) on GTPase leads to tryptophan fluorescence 
change. Here four Sec7-containing ARNO constructs were tested as GEFs in exchange 
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assay: Sec7, Sec7(4A), ARNO and ARNOΔPBR. Assay was performed at room 
temperature as described in Methods section. Briefly, His-NΔ17Arf1 was preloaded with 
GDP, before being combined with different ARNO constructs or assay buffer as negative 
control. GTP addition started exchange reaction, in which tryptophan fluorescence change 
was monitored every 10 second for 15min, with excitation wavelength of 280nm and 
emission wavelength of 340nm. One can clearly see that Sec7 has the highest exchange 
activity, showing fastest tryptophan fluorescence increase (Figure 3.24). 4A mutation 
effectively destroys exchange activity of Sec7, since its time trace is as flat as buffer 
control. Details about 4A mutation will be elaborated in section 3.2.3.4. The time trace of 
ARNO looks flat as well, probably due to the autoinhibition by Sec7-PH linker and C-
terminal helix, which fold back to Sec7 and obstruct docking of Arf1. On the other hand, 
deletion of PBR in ARNOΔPBR partially restores its exchange activity towards Arf1. 
Qualitatively speaking, the data obtained here fit well with the published catalytic 
efficiency data (DiNitto et al., 2007). All constructs are suited to further interaction study.  
 
 
Figure 3.24 Guanine nucleotide exchange assay of various ARNO constructs with Arf1. Indicated 
ARNO proteins or buffer was combined with GTPase His-NΔ17Arf1 for the assay. Tryptophan 
fluorescence increase upon nucleotide exchange was monitored by Tecan plate reader at 340nm 
for 15min. Triplicates in each dataset are displayed as dots and error bars, representing mean and 
standard deviation, respectively. RFU: relative fluorescence units.   
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3.2.3 Investigation of interaction between EGFR-ICD and ARNO 
In order to investigate interaction between EGFR-ICD and ARNO, MST assay was 
performed, because it is free of immobilization compared to surface plasmon resonance 
(SPR), and with minimal protein consumption compared to isothermal titration calorimetry 
(ITC). In addition, compared to other protein-protein interaction analyses such as 
crosslinking and label transfer, MST is much faster, taking only less than 30min for one 
complete assay, whereas the former two need hours up to one day. Standard MST assay, 
which has been applied to this thesis project, is introduced in detail concerning both 
principle and practice in Methods section. On the other hand, label-free MST, which 
exploits intrinsic tryptophan fluorescence of one protein for detection but requires the 
other to be tryptophan-free, was not performed here due to the presence of tryptophans in 
both EGFR-ICD and ARNO. 
3.2.3.1 ICD interacts with ARNOΔPBR 
The protein-protein interaction study begins with MST measurement of ICD with ARNO, 
ARNOΔPBR or ARNO-PH, aiming at establishing ICD:ARNO interaction and locating the 
ICD-binding site on ARNO.  
 
Figure 3.25 MST binding assay of ICD with ARNO, ARNO-PH or ARNOΔPBR. Three independent 
measurements in each dataset are merged and displayed as points and error bars, which 
represent means and standard deviations of ΔFnorm at each concentration, respectively. Single 
MST measurements are plotted as scatter graphs in Appendix Figure S2. 
Detailed labeling and MST procedures can be found in Methods section. ICD was labeled 
by fluorescent dye Red-NHS 2nd Generation, with degree of labeling (DOL) determined 
as 1.41 via NanoDrop. Assay was conducted at 25℃ in MST buffer (20mM HEPES 
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pH7.8, 150mM NaCl, 0.005% TritonⓇ X-100, 10μM BSA) with 20% excitation power and 
40% MST power. Concentration of labeled ICD was held at 100nM, whereas 
concentration of ARNO, ARNOΔPBR and ARNO-PH varied by 1:3 serial dilution, starting 
from 115μM for ARNO and ARNOΔPBR, 106μM for ARNO-PH.   
As shown in Figure 3.25, ICD recognizes ARNOΔPBR displaying a nice binding curve and 
Kd of 12.5μM according to dose response fitting of MO.Affinity Analysis. Conversely, 
ICD:ARNO and ICD:ARNO-PH bear no clear sign of binding, with ΔFnorm values all 
distributed close to zero, and dose response fitting unable to return reasonable values. 
Altogether, these three datasets reveal that ICD interacts with ARNOΔPBR, but not with 
ARNO or ARNO-PH. PH domain is clearly ruled out as the binding site for ICD. 
Furthermore, distinct MST results of ARNO and ARNOΔPBR could be explained by their 
structural difference due to autoinhibition, with Sec7 domain in ARNO shielded and in 
ARNOΔPBR more exposed, suggesting Sec7 as the potential binding site for ICD. 
However, direct measurement of ICD:Sec7 interaction is needed to support this.  
3.2.3.2 ICD binds to ARNO-Sec7 
The goal of this section is two-fold. First, to investigate direct interaction between ICD and 
Sec7, as discussed in last section. Second, to identify the Sec7-binding site on ICD, if 
direct interaction is confirmed. Since the known cytoplasmic modulators of EGFR target 
either juxtamembrane segment (calmodulin and TRAF4; Aifa et al., 2002; Cai et al., 2018; 
Martín-Nieto and Villalobo, 1998) or its kinase domain (Mig6; Park et al., 2015; Zhang et 
al., 2007), ICDΔJM27 was included in this section to first test whether JM could be the 
binding site for Sec7. In ICDΔJM27, only first 27 amino acids are deleted instead of the 
whole 38 amino acids of JM, because these extra 11 amino acids are viewed as an 
integral part of the kinase core and routinely retained in constructs for structural and 
functional studies (Jura et al., 2009; Stamos et al., 2002; Zhang et al., 2006). 
ICDΔJM27 was labeled by fluorescent dye Red-NHS 2nd Generation following the same 
procedure as ICD, with DOL determined via NanoDrop as 1.13. MST assay was 
performed with ICD:Sec7 and ICDΔJM27:Sec7 pairs, under the same buffer condition and 
measurement setup as described in previous section. Concentration of labeled ICD and 
ICDΔJM27 was held constant at 100nM, while concentration of Sec7 varied by 1:3 serial 
dilution, starting from 389μM.  
One can clearly see that ICD interacts with Sec7 but ICDΔJM27 does not, even though 
weak interaction at the highest Sec7 concentrations cannot be fullly excluded (Figure 
3.26). For ICD:Sec7 pair, dose response fitting of MO.Affinity Analysis returns Kd of 
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49.2μM. In contrast, ICDΔJM27:Sec7 measurement provides ΔFnorm values all around 
zero, except last two data points with highest Sec7 concentrations. For this scatter plot, 
software fails to execute dose response fitting. To conclude, ICD does interact with Sec7 
directly and JM could be the Sec7-binding site of ICD. However, there is another 
possibility that JM-mediated ICD dimerization forms a new protein surface that binds to 
Sec7 and such surface is not present in ICDΔJM27. To resolve this issue, a direct MST 
measurement of Sec7:JM pair is necessary. Moreover, it is noteworthy that Kd of 
ICD:Sec7 here is higher than ICD:ARNOΔPBR pair measured in previous section. Since 
PH domain has been excluded as binding site for ICD, the stronger affinity of ARNOΔPBR 
towards ICD could be ascribed to N-terminal coiled-coil segment as additional binding 
site, or ARNO dimerization driven by coiled-coil segment. As shown in Figure 3.23, ICD at 
100nM still function as dimers to phosphorylate each other. Therefore, under MST assay 
conditions, both ARNOΔPBR and ICD exist in dimeric form, and the dimer-dimer 
interaction may further stabilize ICD:ARNOΔPBR complex, giving stronger apparent 
affinity. On the other hand, Sec7 exists only as monomer and will not enjoy such 
additional contribution to binding affinity.  
 
Figure 3.26 MST binding assay of ICD or ICDΔJM27 with Sec7. Three independent 
measurements in each dataset are merged and displayed as points and error bars, which 
represent means and standard deviations of ΔFnorm at each concentration, respectively. Individual 
MST measurements are plotted as scatter graphs in Appendix Figure S2. 
3.2.3.3 Sec7 interacts with JM peptide directly 
As discussed in section 3.2.3.2, Sec7:JM pair should be measured via MST, in order to 
ascertain that JM segment is the Sec7-binding site on ICD. A scrambled version of JM 
peptide, i.e. the same amino acids but in random sequence, JMsc, was included in control 
measurement as Sec7:JMsc pair.  
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Labeling and MST procedures are described in Methods section. Briefly, Sec7 was 
labeled by Alexa FluorTM 647 NHS Ester, with DOL determined as 0.746. MST was 
performed with 60% excitation power and 50% MST power. Concentration of labeled 
Sec7 was held at 100nM, and concentration of JM and JMsc varied by 1:3 serial dilution, 
starting from 320μM.  
As depicted in Figure 3.27, Sec7 binds directly to JM peptide with Kd of 49.6μM. On the 
other hand, data from Sec7:JMsc pair could not be fitted by MO.Affinity Analysis. Kd of 
Sec7:JM agrees surprisingly well with Kd of ICD:Sec7 interaction (49.2μM), considering 
labeling conditions and MST setup are very different between these two pairs, which 
supports the argument that Sec7 binds to ICD on its JM segment. Since JM has  a basic 
isoelectric point whereas Sec7 has an acidic pI (11.91 and 6.38, respectively), one could 
assume unspecific electrostatic interaction of both. However, MST result of Sec7:JMsc 
excludes the possibility that Sec7 interacts with JM via pure electrostatic attraction, and 
shows this interaction is sequence-dependent. Further characterization of Sec7:JM 
interaction on amino acid level shall be elaborated in Discussion section, combined with 
NMR data from collaborators.   
 
Figure 3.27 MST binding assay of Sec7 with JM or scrambled JM (JMsc). Three independent 
measurements in each dataset are merged and displayed as points and error bars, which 
represent means and standard deviations of ΔFnorm at each concentration, respectively. Individual 
MST measurements are plotted as scatter graphs in Appendix Figure S2. 
3.2.3.4 Sec7 mutation undermines interaction with ICD and JM 
In collaboration with Dr. Manuel Etzkorn and Dr. Aldino Viegas, Sec7:JM interaction was 
intensively studied via NMR spectroscopy. One of the conclusions from NMR study is that 
part of the JM-binding site of Sec7 lies in αH-helix (helix nomenclature from Mossessova 
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et al., 1998), which also participates in Arf1 docking (Cherfils et al., 1998; Mossessova et 
al., 1998; Renault et al., 2003) and autoinhibition mechanism (DiNitto et al., 2007) via its 
hydrophobic patch. It would be interesting to find out whether alanine mutations at these 
hydrophobic residues impair Sec7:JM interaction. In this section, a mutant construct 
Sec7(4A) was studied via MST, containing Y186A, F190A, I193A and M194A mutations in 
αH-helix.  
Detailed MST protocol is described in Methods section. Sec7(4A) was labeled by Alexa 
FluorTM 647 NHS Ester, with DOL of 1.08. For Sec7(4A):JM interaction, MST was 
performed with 60% excitation power and 50% MST power. Concentration of labeled 
Sec7 was held at 100nM, and concentration of JM varied by 1:3 serial dilution, starting 
from 320μM. For ICD:Sec7(4A) interaction, ICD labeled by Red-NHS 2nd Generation 
(same batch as in previous sections) was measured, with 20% excitation power and 40% 
MST power. Each capillary contained 100nM labeled ICD and 1:3 serially diluted 
Sec7(4A) starting at 389μM.  
In Figure 3.28 (A), there is no binding event, with all data values fluctuating about zero. In 
Figure 3.28 (B), labeled-ICD shows some dose response to high concentration of 
Sec7(4A), but it is nothing like a saturated biding curve, and software fails to execute dose 
response fitting. Considering the highest Sec7(4A) concentration is 389μM, even there is 
any possible binding, it would be a really weak one, compared to ICD:Sec7 data from 
section 3.2.3.2. Therefore, 4A mutation effectively undermines Sec7:JM and ICD:Sec7 
interaction, supporting the observation from NMR study.  
 
Figure 3.28 MST binding assay of Sec7(4A) with JM and ICD with Sec7(4A). Three independent 
measurements in each dataset are merged and displayed as points and error bars, which 
represent means and standard deviations of ΔFnorm at each concentration, respectively. Individual 
MST measurements are plotted as scatter graphs in Appendix Figure S2. 
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3.2.4 Competition study between calmodulin and Sec7 
It has long been known that calmodulin (CaM for short) interacts with JM segment of 
EGFR (Aifa et al., 2002; Martín-Nieto and Villalobo, 1998). The common binding site on 
EGFR raises the question of whether calmodulin could compete against Sec7 for binding 
towards JM. To answer this question, MST binding assay of ICD:CaM pair should be 
performed first.  
3.2.4.1 Calmodulin binds to JM of ICD in a Ca2+-dependent manner 
The purpose of the ICD:CaM binding assay is two-fold: to confirm ICD:CaM interaction via 
MST, and to decide proper dose of CaM for the competition assay. 
Description of MST is in Methods section. The same batch of ICD and ICDΔJM27 labeled 
in previous sections by Red-NHS 2nd Generation was used here. Since ICD:CaM 
interaction is known to be Ca2+-dependent, one control of ICD:CaM in EGTA-containing 
buffer was tested in MST, in addition to ICD:CaM and ICDΔJM27:CaM measurements in 
CaCl2-containing buffer. MST was performed with 20% excitation power and 40% MST 
power. Concentrations of labeled ICD and ICDΔJM27 were held at 100nM, and 
concentration of calmodulin varied by 1:2 serial dilution, starting from 65μM.   
In the presence of CaCl2, ICD binds nicely to calmodulin with Kd of 0.76μM (Figure 3.29), 
close to published values (Aifa et al., 2002; Li and Villalobo, 2002; Martín-Nieto and 
Villalobo, 1998). According to the Kd values acquired so far, CaM has stronger affinity 
toward ICD than Sec7 does (0.76μM vs. 49.2μM), so it is easier to see CaM inhibiting 
ICD:Sec7 interaction than Sec7 inhibiting ICD:CaM interaction. Therefore, CaM is chosen 
as the competitor in the following competition assay. In control measurement with 2mM 
EGTA, ICD:CaM interaction is completely abandoned, and all ΔFnorm values fluctuate 
around zero. Furthermore, ICDΔJM27:CaM in the presence of 2mM CaCl2 also shows no 
sign of binding. The last two data points on the right are drifted away from zero, which 
could be attributed to unspecific binding to ICDΔJM27 at high calmodulin concentrations, 
while the third point to the right with 15μM calmodulin does not show unspecific binding. In 
ICD:CaM (CaCl2), the data point at the same calmodulin concentration (15μM) lies in the 
saturation phase of the binding curve. So 15μM is the optimal concentration for 
competition assay, for it reaches binding saturation without any unspecific interaction. To 
conclude, the MST assay in this section has proven that ICD recognizes CaM in a JM- 
and Ca2+-dependent manner, with 15μM calmodulin determined as the optimal competitor 
for competition assay.  
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Figure 3.29 MST binding assay of ICD or ICDΔJM27 with calmodulin. ICD:CaM was measured in 
the presence of 2mM CaCl2 or 2mM EGTA, while ICDΔJM27:CaM was measured in the presence 
of 2mM CaCl2. Three independent measurements in each dataset are merged and displayed as 
points and error bars, which represent means and standard deviations of ΔFnorm at each 
concentration, respectively. Individual MST measurements are plotted as scatter graphs in 
Appendix Figure S2.  
3.2.4.2 Calmodulin and Sec7 compete for binding to ICD  
MST procedure is described in Methods section. Assay was performed in buffer 
containing 2mM CaCl2, with 20% excitation power and 40% MST power. The same batch 
of ICD labeled by Red-NHS 2nd Generation was used here. In both “+ CaM” and “-CaM” 
measurements, labeled ICD was held at constant concentration of 100nM, while Sec7 
concentration varied by 1:3 serial dilution, starting from 389μM. In “+ CaM”, 30μM of 
calmodulin was pre-incubated with labeled ICD at RT for 5min, before being mixed with 
equal volume of serially diluted Sec7.   
ICD:Sec7 interaction gives a nice binding curve with Kd of 68.4μM, not far from 49.2μM 
determined in section 3.2.3.2. The competition of 15μM calmodulin undermines this 
interaction, leaving no sign of binding in “+ CaM” measurement, so CaM successfully 
blocks interaction between ICD and Sec7 (Figure 3.30). However, other than CaM 
competes against Sec7 by binding to ICD, there is an alternative explanation that CaM 
binds to Sec7 and prevents it from interacting with ICD, thus leaving ICD unbound. 
Further data analysis excludes such possibility. As mentioned in Methods section 5.2.6, 
Fnorm,unbound and Fnorm,bound are signatures of two species, i.e. labeled protein alone and 
labeled protein bound to unlabeled protein, respectively. In Figure 3.31, three datasets 
from previous figures are superimposed, with Fnorm instead of ΔFnorm on the Y axis. Within 
each dataset, points close to left end of the plot is viewed as asymptotically approaching 
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Fnorm,unbound, as most of the labeled protein molecules are in  unbound state. Meanwhile, 
points close to right end of the plot is viewed as asymptotically approaching Fnorm,bound, 
where unlabeled protein saturates the binding site on the labeled protein. As revealed in 
Figure 3.31, left ends of “ICD:CaM (CaCl2)” and “ICD:CaM (EGTA)” are both approaching 
Fnorm of 920‰, where labeled ICD is unbound. On the right end of these two groups, 
“ICD:CaM (CaCl2)” is approximating 910‰, signature of ICD-CaM complex; “ICD:CaM 
(EGTA)” is still around 920‰, meaning ICD remains unbound in EGTA-containing buffer. 
Now in “+ CaM” measurement, data points fluctuate around 910‰, which means labeled 
ICD is still in CaM-bound state. That contradicts the alternative explanation and 
corroborates the hypothesis that CaM effectively hinders ICD:Sec7 interaction by directly 
binding to ICD, not to Sec7. Moreover, in “+ CaM”, highest concentration of Sec7 is 
389μM while CaM is only 15μM, which leaves a far-fetched scenario that CaM blocks the 
interaction by directly binding to such massive amount of Sec7.   
 
Figure 3.30 MST assay with calmodulin competition. “- CaM” indicates ICD:Sec7 interaction 
without CaM, and “+ CaM” indicates ICD:Sec7 with CaM as competitor. Assay was performed in 
buffer containing 2mM CaCl2. Three independent measurements in each dataset are merged and 
displayed as points and error bars, which represent means and standard deviations of ΔFnorm at 
each concentration, respectively. Individual MST measurements are plotted as scatter graphs in 
Appendix Figure S2.  
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Figure 3.31 Superimposition of previous MST results. Three datasets from Figure 3.29 and Figure 
3.30 are replotted as Fnorm vs. Constructs concentration, and labeled according to the same 
nomenclature as in original figures. Three independent measurements in each dataset are merged 
and displayed as points and error bars, which represent means and standard deviations of Fnorm at 
each concentration.  
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4 Discussion 
4.1 PELDOR: a suitable tool for EGFR conformation study  
In EGFR conformation study (section 3.1), PELDOR has revealed a single conformation in 
all tested constructs, be it soluble MBP-tagged ICD or SBP-tagged near-full-length 
EGFRΔC in micelles. The spin-spin distance agrees with that of crystallized asymmetric 
dimer (PDB ID: 2J5F) very well. Unlike crystallography, NMR and fashionable cryo-EM, 
which provide all-atom structure of protein, PELDOR accurately measures the interspin 
distance in spin-labeled protein, and delivers key information such as inter-/intramolecular 
conformation changes in response to different conditions (Glaenzer et al., 2017) or 
location of metal ion cofactor critical for catalysis (Abdullin et al., 2015). As is known, 
crystallography relies upon the unpredictable outcome of protein crystallization screening, 
NMR is mainly limited to protein smaller than 50kDa (reviewed by Frueh et al., 2013) with 
additional stability and concentration requirement, and cryo-EM has an expected lower 
mass limit of 38kDa (reviewed by Henderson, 1995). In contrast, PELDOR analyzes 
samples in solution, has no protein size limit, and can be readily applied to various 
conditions such as detergent, lipid and even cellular environments. The distinctive 
features make PELDOR a powerful tool complementary to other structural biology 
techniques. For example, EGFR conformation study in this thesis started from analyzing 
available cocrystal structure of ICD-PD168393 (PDB ID: 2J5F) and molecular dynamics 
(MD) simulation files (Arkhipov et al., 2013). By carefully inspecting binding mode of the 
inhibitor, and calculating the theoretical interspin distances via mtsslWizard, it was proven 
to be feasible to employ a spin-labeled inhibitor for PELDOR measurement. Later on, 
PELDOR provided experimental data that faithfully reflect crystal structure of the 
asymmetric dimer. In this project, crystallography and MD simulation provide protein 
structure for PELDOR spin label design, while PELDOR extends the conformation 
observed in densely packed crystal or in silico to dilute solution and detergent 
environments. Potentially PELDOR could also study the structural change of EGFR 
triggered by various factors, e.g. EGF or calmodulin. The dynamic process would be 
characterized via freeze-quenching technique (reviewed by Cherepanov and De Vries, 
2004), by measuring distances from samples obtained at certain intervals over a time 
period, which is beyond the “snapshot” structure from a crystal and might support 
predictions from simulation. Therefore, this conformation study of EGFR is an exemplary 
case of integrative structural biology where individual techniques are incorporated to 
address challenging issues from multiple perspectives.  
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Concerning macromolecular distance measurement, fluorescence resonance energy 
transfer (FRET) has long been known to have the potential as a distance ruler. The 
optimal range for energy transfer is 10-80Å (reviewed by Truong and Ikura, 2001), similar 
to the measurement range of PELDOR, and both methods are not constrained by protein 
size. However, FRET is more sensitive due to the strong fluorescence signal, which 
allows detection at single molecule resolution (Hellenkamp et al., 2018). Routinely running 
at room temperature on liquid solution, FRET in some cases can even monitor target 
protein from living cells in real time (Mohamed et al., 2018; reviewed by Stumpf and 
Hoffmann, 2016). The transfer efficiency of FRET is 1/[1+(r/R0)6] with r being the distance 
between fluorophores and R0 being Förster radius which in part depends on the relative 
orientations between fluorophores (reviewed by Dimura et al., 2016). However, the value 
of orientation factor is assumed, which adds inaccuracy to the final distance (Schiemann 
et al., 2004). Also, fluorescence intensity during measurement may be influenced by other 
factors such as quenching, which requires additional experiment design and data 
interpretation to eliminate such effects. Furthermore, FRET fluorophores are often 
designed with longer linker than EPR spin labels, which makes distance between 
fluorescence centers less defined and more difficult to accurately derive (reviewed by 
Dimura et al., 2016). In contrast, PELDOR spectroscopy is less sensitive but more 
quantitative about the distance of interest. Unlike FRET, PELDOR measurement is 
typically performed on samples in frozen solution, with more protein molecules required 
for sufficient signal, e.g. 7.8×1014 molecules for PELDOR in this thesis. During the 
measurement, the spin orientation selectivity can be inspected by recording time traces at 
different frequency offsets and distance is calculated without assuming any parameters. 
Additionally, spin labels are generally smaller than fluorophore and coupled with shorter 
linker, which means less disruption to the protein structure and more accurate 
measurement of interspin distance due to structural rigidity.  
In current PELDOR project of this thesis, accurate distance distribution is desired to 
enable a comparison with published crystal structure and simulations for identifying EGFR 
conformation. Moreover, adequate amount of proteins was enriched via purification 
procedure to compensate for the relatively low sensitivity of PELDOR. However, for the 
potential in-cell PELDOR measurement, higher sensitivity is appreciated due to the low 
EGFR abundance in cells. Also, traditional nitroxide labels face the challenge of cellular 
reducing environment. In that case, other strategies could serve as remedies, which will 
be discussed in next section. To sum up, PELDOR demands modest amount of protein 
without restriction of the size, requires sample preparation in either frozen solution or 
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other diverse environments, and it accurately measures distance in the range of 18-80Å. 
Taken together, PELDOR serves as a suitable tool for EGFR conformation study. 
4.2 Attempts of in-cell and in-membrane PELDOR 
After the success of PELDOR measurements on purified proteins, it would be more 
interesting to see whether the same observations could follow in living cells or cellular 
membrane. Such data under the more native conditions would add more credit to the 
conclusions drawn so far from in vitro samples. Although in-cell PELDOR has been 
performed in several studies (Azarkh et al., 2011a; Theillet et al., 2016), it still faces 
several technical challenges such as cell-permeability of the compound, higher demand 
for labeling specificity in cells compared to purified samples, the reducing cellular 
environment which destabilizes common nitroxide spin labels and low copy number of 
target protein in cells. According to a preliminary in-house test, cellular EGFR 
autophosphorylation is effectively inhibited upon addition of PDsl to the cell culture 
medium, so PDsl is cell-permeable. Furthermore, clinical EGFR kinase inhibitors, many of 
which are structurally analogous to PD168393, have shown high selectivity in a chemical 
proteomics study (Klaeger et al., 2017). Concerning the spin label stability, it has been 
shown that six-membered-ring nitroxides are less resistant to reducing cellular condition 
than their five-membered-ring cousins (Azarkh et al., 2011b; Krstic et al., 2011). 
Additionally, it has been estimated that half-life of a five-membered-ring nitroxide, i.e. 
PROXYL, in oocytes of Xenopus laevis is roughly 50min (Igarashi et al., 2010). Thus spin 
labeling of cells is achievable if PDsl, which contains a five-membered-ring nitroxide, is 
incubated with cells and frozen in PELDOR tube as soon as possible. However, literature 
research indicates that the cellular copy number of EGFR may not be enough for 
PELDOR measurement. Based on classical saturation method and kinetic extrapolation 
technique, it has been revealed that A431, a human carcinoma cell line, contains 
approximately 2×106 copies of EGFR per cell (Barta et al., 2011; Novy et al., 2012). 
Considering that 2×107 cells reach maximum volume of 100μL that can be measured in 
PELDOR Q-band tube, the equivalent EGFR concentration is 0.66μM, which is still below 
the detection limit. Indeed, pilot experiments showed that by this approach no modulation 
depth for PDsl-labeled EGFR could be observed. So the plan of in-cell PELDOR was 
aborted.  
Consequently, the alternative plan of in-membrane PELDOR was initiated. In this plan, 
heavy nuclei were removed as pellet from disrupted cells after 1000g centrifugation and 
cytosol was subsequently discarded after 75000g centrifugation as supernatant. Acquired 
pellet containing plasma membrane was resuspended and labeled by PDsl. It was hoped 
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that by discarding nuclei and cytosol, there would be additional space for more EGFR-
containing membranes in the PELDOR tube. However, protein quantification via western 
blot indicates that enriched EGFR is not enough for PELDOR. During the sample 
resuspension, membrane sample has proven to be intractable and sticky, which explains 
the heavy loss of EGFR during this procedure.   
So far the effort of measuring EGFR PELDOR under cellular or membrane conditions is 
stalled. One of the bottlenecks is the low EGFR concentration in enriched samples. This 
obstacle, however, could be in future overcome by using EGFR-overexpressing cell lines 
or improving membrane enrichment protocol. The other limiting factor is the stability of 
nitroxide spin label in reducing cellular environment. Until now several new spin labels 
have been developed and shown to be resistant towards reducing environment, such as 
Gd3+-complex (Qi et al., 2014), triarylmethyl (trityl) radicals (Jassoy et al., 2017; Shevelev 
et al., 2014) and tetraethyl-substituted nitroxides (Jagtap et al., 2015). Due to the smaller 
size and improved reductive stability, tetraethyl-substituted nitroxides promise to be the 
proper candidate for in-cell EPR in future.  
4.3 Influence of inhibitors over EGFR conformation equilibrium 
Previous studies have shown asymmetric and symmetric dimers of EGFR kinase domain 
from either crystal structures (Jura et al., 2009; Zhang et al., 2006) or negative-stain EM 
images (Mi et al., 2011). Although interspin distances for both conformations are 
measurable in PELDOR, only one peak corresponding to asymmetric dimer was observed 
in frozen solution. Two possible reasons would be either PDsl  does not fit into the ATP-
binding sites of symmetric dimer, or it prefers to bind to asymmetric dimer and thereby 
shifts the conformation equilibrium. First possibility is ruled out by modeling via 
mtsslWizard and comparing volumes occupied by each spin label ensemble in symmetric 
and asymmetric dimers (Yin et al., 2017). Therefore, PD168393-based spin label disrupts 
EGFR conformation equilibrium in solution by stabilizing asymmetric dimer.  
PD168393 belongs to one group of EGFR kinase inhibitors which are based on 
anilinoquinazoline backbone. Early studies of quinazoline inhibitors such as PD153035, 
AG-1478 and AG-1517 have indicated that they could increase EGFR dimerization 
(Arteaga et al., 1997; Lichtner et al., 2001). Several published crystal structures later 
reveal that two groups of quinazoline inhibitors exist, which favor either active or inactive 
kinase conformation of EGFR (Blair et al., 2007; Stamos et al., 2002; Wood et al., 2004). 
Among them are cocrystals of ICD(672-998) with PD168393 (PDB ID: 2J5F) or lapatinib 
(PDB ID: 1XKK; Wood et al., 2004).  
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Figure 4.1 Crystal structures of EGFR kinase core in complex with PD168393 (A) or lapatinib (B). 
Kinase core, i.e. ICD(672-998), is depicted as dark green (A) or cyan (B) cartoon. PD168393 and 
lapatinib are shown as sticks with carbons colored yellow. Relevant residues are labeled and 
shown as sticks with carbons colored magenta. Activation loops are colored orange and αC-helices 
are shown as pink. Note the different orientations of αC-helices in (A) and (B). Fragment between 
L694 and T701 spanning the glycine-rich loop is removed to view ATP-binding site more clearly. 
Sequence numbering is based on human EGFR without signal peptide. Figure was prepared from 
PDB ID: 2J5F (A) and 1XKK (B) with PyMOL Molecular Graphics System. 
 
 
Figure 4.2 Chemical structures of four EGFR kinase inhibitors. Quinazoline backbones are 
numbered. Figure was prepared with ChemDraw.  
For PD168393, the acrylamide warhead reacts with sulfhydryl group of C773 nearby via 
Michael addition, hence the irreversible binding. Meanwhile, quinazoline N1 forms a 
hydrogen bond with backbone amide of M769, while 4-aniline reaches into hydrophobic 
pocket around gatekeeper residue T766, stabilizing kinase domain in its active form, 
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evidenced by intact K721-E738 salt bridge and “αC-helix in” conformation, as shown in 
Figure 4.1 (A). Interaction mode of reversible inhibitor lapatinib retains N1 hydrogen bond, 
whereas quinazoline N3 forms a new water-mediated hydrogen bond with T830. The 
bulkier substitution on 4-aniline is accommodated in the hydrophobic pocket by “αC-helix 
out” conformation, in which αC-helix is oriented away from the ATP-binding site, as shown 
in Figure 4.1 (B). This αC-helix shift and loss of K721-E738 salt bridge indicate inactive 
kinase conformation and stay in clear contrast to the kinase structure in Figure 4.1 (A). 
Similarity and difference between these two groups of inhibitors are further illustrated in 
Figure 4.2, where structures of four compounds (erlotinib, gefitinib, PD168393 and 
lapatinib) are drawn and compared. On the common anilinoquinazoline backbone, N1 is 
conservative due to the critical hydrogen bond. Substitutions on C6 and C7 are quite 
diverse, because they face outwards from the ATP-binding cleft, therefore with less 
structural restriction. What distinguishes lapatinib from others is the substitution on 4-
aniline. One additional aromatic ring is tethered to 4-aniline, and this flexible yet much 
bulkier substitution leads to distinct αC-helix conformation as explained in Figure 4.1.  
 
Figure 4.3 Overview of asymmetric dimer formed within kinase core-PD168393 cocrystal. Kinase 
core, i.e. ICD(672-998), is depicted as dark green or dark blue cartoon in either monomer. 
PD168393 is shown as sticks with carbons colored yellow. Relevant residues are labeled and 
shown as sticks with carbons colored magenta. Activation loops are colored orange and αC-helices 
are shown as pink. N-lobe and C-lobe of kinase domain are labeled. Sequence numbering is based 
on human EGFR without signal peptide. Figure was prepared from PDB ID: 2J5F with PyMOL 
Molecular Graphics System.  
Activation loop
Activation loop
αC-helix
αC-helix
M769
M769
C773
C773
K721
K721
E738
E738
C-lobe
N-lobe
N-lobe
C-lobe
Discussion 
 
 57 
 
Figure 4.4 Superimposition of two kinase dimer structures. Asymmetric dimer from kinase core-
PD168393 cocrystal (dark green) superimposed on that from kinase core-substrate analog 
cocrystal (orange). PD168393 and substrate analog are omitted. N-lobe and C-lobe of kinase 
domain as well as αC-helix are labeled. Figure was prepared from PDB ID: 2J5F and 2GS6 with 
PyMOL Molecular Graphics System.  
According to the allosteric activation mechanism of EGFR, active kinase conformation is 
associated with asymmetric dimerization (reviewed by Bose and Zhang, 2009). Indeed, it 
has been reported that the first group of quinazoline inhibitors such as PD168393, which 
stabilizes active kinase conformation, can cause asymmetric kinase dimerization. In 
contrast, second group of inhibitors like lapatinib, which favors inactive kinase 
conformation, promotes no kinase dimerization (Lu et al., 2012). Especially, PD168393-
induced dimerization is abolished by V924R mutation, with only monomeric EGFR on gel 
filtration chromatogram (Lu et al., 2012), which is consistent with our PELDOR and gel 
filtration data. The asymmetric dimer is also observed in the cocrystal with PD168393 
(PDB ID: 2J5F), as illustrated in Figure 4.3, where two neighboring active kinase 
monomers are oriented in head-to-tail fashion, with activator C-lobe contacting receiver N-
lobe. As a comparison, 2J5F is superimposed on another crystal structure (PDB ID: 
2GS6), which contains ICD(672-998) in active kinase conformation in complex with ATP 
analog-peptide conjugate. As can be seen in Figure 4.4, two structures align well, 
especially so in the αC-helix region, thus confirming asymmetric dimerization. Conversely, 
no asymmetric dimer is observed in cocrystal with lapatinib (PDB ID: 1XKK). Although not 
causing aberrant kinase dimerization in the absence of EGF, lapatinib suppresses 
asymmetric dimerization in the presence of EGF, as revealed by negative-stain EM of a 
nearly full-length EGFR construct (Mi et al., 2011), probably by blocking formation of 
active kinase conformation with its bulky substitution on 4-aniline.  
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As EPR probe, spin label is supposed to be a neutral observer. It should remain unbiased 
towards conformations in equilibrium, reporting structures without disturbing them. Yet as 
discussed, it is not quite the case for PDsl,  and probably not for lapatinib-based spin label 
either. On the other hand, PELDOR data from frozen solution accurately report 
asymmetric dimer observed in crystallization and EM studies, thereby confirming inhibitor-
mediated dimerization discussed in other publications (Arteaga et al., 1997; Blair et al., 
2007; Lichtner et al., 2001; Lu et al., 2012; Mi et al., 2011). From this perspective, effects 
of other EGFR inhibitors over its kinase conformation equilibrium can be investigated via 
PELDOR in future, with the help of IDSL. But still, an unbiased EPR probe is optimal for 
EGFR conformation study.  
 
Figure 4.5 Chemical structures of representative third-generation EGFR kinase inhibitors. 
Anilinopyrimidine backbones are shaded in cyan, and acrylamide moieties are shaded in pink. 
Figure was prepared with ChemDraw.  
At this moment, attention was drawn to the new generation of EGFR inhibitors. As is well 
known, erlotinib, gefitinib, lapatinib and PD168393 represent first- and second-generation 
EGFR kinase inhibitors, which share a common quinazoline core but differ in binding 
reversibility. During treatment with these inhibitors, patients often develop drug resistance 
via acquired secondary mutations like T766M. The third generation irreversible inhibitors, 
such as AZD9291, CO-1686 and WZ4002 (Figure 4.5), were developed with new 
anilinopyrimidine backbone to fight against such mutations (Cross et al., 2014; Engel et 
al., 2015; Walter et al., 2013; Zhou et al., 2009). They retain acrylamide moiety for the 
Michael addition with C773, but vacate the space occupied by 4-aniline on quinazoline 
backbone to tolerate the longer side chain of M766. As noticed in Figure 4.6 (A), the 
binding mode of WZ4002 (PDB ID: 3IKA; Zhou et al., 2009) is somewhat similar to that of 
the substrate analog in Figure 4.6 (C), both having no major contact with hydrophobic 
pocket adjacent to the gatekeeper residue T766. Therefore, question has arisen of 
whether this analogy means that WZ4002 has less disruption to EGFR kinase 
conformation equilibrium and qualifies as a candidate for IDSL probe design. Downside is 
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that the third generation inhibitors are mutant-selective, so it is  doubted that they could 
bind and inhibit wildtype kinase equally effectively. Indeed as reported, quinazoline-based 
inhibitors are 100-fold more potent than WZ4002 when tested on wildtype kinase (Zhou et 
al., 2009). Therefore, as part of the follow-up plan for PDsl, inhibition potency of 
compounds like WZ8004 should be tested first. If it is indeed not so effective against 
wildtype kinase, incubation procedure could be optimized to achieve better binding of the 
inhibitor (more inhibitor input, longer incubation time, etc.). In the meantime, more effort 
should be spent on searching for derivatives of these inhibitors with better potency against 
wildtype kinase.   
 
Figure 4.6 Comparison of binding modes of WZ4002 (A), PD168393 (B) and ATP analog-peptide 
conjugate (C) to kinase core wildtype or T766M mutant. Kinase core, i.e. ICD(672-998) is depicted 
as dark green cartoon. WZ4002, PD168393 and ATP analog-peptide conjugate are shown as 
sticks with carbons colored yellow. C773 and gatekeeper residue T766 or M766 are labeled and 
shown as sticks with carbons colored magenta. Fragment between L694 and T701 spanning the 
glycine-rich loop is removed to view ATP-binding site more clearly. Sequence numbering is based 
on human EGFR without signal peptide. Figure was prepared from PDB ID: 3IKA (A), 2J5F (B) and 
2GS6 (C) with PyMOL Molecular Graphics System. 
Another direction would be considering nucleotide-based probe. Since ATP is the natural 
ligand that fits into the activity site, it seems reasonable to design a probe simply with 
nitroxide radical tethered to ATP. Yet Km of ATP towards EGFR is in the range of 1-10μM 
(Honegger et al., 1988), which hinders application of spin-labeled ATP in PELDOR. As 
reported in our previous study, a spin-labeled ATP with spin marker attached to 2’-OH of 
the ribose shows no modulation of PELDOR time trace (Yin et al., 2018). A second 
nucleotide-based labeling strategy is built upon biotinylated acyl ATP or ADP (Figure 4.7), 
in which an acyl phosphate is situated between nucleotide and biotin tag. Nucleotide 
functions as binding moiety towards kinase domain, while biotin tag is the labeling group 
which can be switched into nitroxide radical for EPR measurement. Carbonyl carbon of 
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the acyl phosphate acts as electrophile and attacks specifically ε-amino group of a 
conservative lysine near the ATP-binding cleft, after which nucleotide moiety leaves and 
an amide bond forms between biotin tag and lysine residue (Patricelli et al., 2007). In 
Figure 4.8 (A), crystal structure of EGFR kinase with ATP analog-peptide conjugate (PDB 
ID: 2GS6) shows that only one lysine residue K721 is close to ATP β- or γ-phosphate, 
with around 8Å between terminal nitrogen of lysine side chain and phosphorus of γ-
phosphate. This lysine is conserved in CDK2 (PDB ID: 1HCK; Schulze-Gahmen et al., 
1996) as K33 in Figure 4.8 (B), with another lysine K129 located in the proximity as well. 
In EGFR, however, an arginine residue R817 occupies the location corresponding  to 
K129 of CDK2. Further inspection of other kinase structures reveals that this arginine is 
conserved across tyrosine kinases such as insulin receptor kinase (PDB ID: 3BU5; Wu et 
al., 2008) or ABL1 kinase (PDB ID: 3CS9; Weisberg et al., 2005), whereas K129 of CDK2 
is conserved in serine/threonine kinases like MAP kinase (PDB ID: 4ZSG; Chen et al., 
2016). In contrast, K721 of EGFR is conserved in both tyrosine and serine/threonine 
kinases. However, K721 is known to be critical for maintaining active EGFR kinase 
conformation as discussed before, so modification of it would be detrimental to kinase 
activity, which makes this labeling strategy not acceptable for EGFR. On the other hand, 
acyl ATP probe could in future be re-engineered for EPR conformation studies of 
serine/threonine kinase, considering that one additional lysine like K129 in CDK2 is 
available and it can be selectively labeled due to closer proximity to γ-phosphate 
compared to K33 (Patricelli et al., 2007).  
 
Figure 4.7 Chemical structures and labeling mechanism of ATP and ADP-based probe. BHAcATP: 
(+)-Biotin-Hex-acyl-ATP, BHAcADP: (+)-Biotin-Hex-acyl-ADP. Figure is adapted from Patricelli et 
al., 2007.  
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Figure 4.8 Comparison of lysine and arginine residues adjacent to ATP-binding sites in EGFR (A) 
and CDK2 (B). EGFR and CDK2 kinases are depicted as dark green (A) and dark blue (B) 
cartoons, respectively. ATP analog-peptide conjugate (A) and ATP (B) are shown as sticks with 
carbons colored yellow. Neighboring lysine and arginine residues are labeled and shown as sticks 
with carbons colored magenta. Glycine-rich loop is removed to view ATP-binding cleft more clearly. 
Figure was prepared from PDB ID: 2GS6 (A) and 1HCK (B) with PyMOL Molecular Graphics 
System. 
4.4 Benefits and limitations of IDSL 
In this thesis project, inhibitor-directed spin label rose from the failure of site-directed spin 
label and witnessed the convenient labeling of EGFR for conformation study. However, 
there are certain issues looming on the horizon which restrict its further application. In this 
section, both benefits and limitations of IDSL will be discussed, with possible solutions or 
alternatives proposed as well.  
One of the major benefits from IDSL is that it liberates scientists from laborious trials and 
errors of mutagenesis work in SDSL. Usage of conventional spin labels like MTSL 
requires optimal cysteine mutations to be sought out for the downstream labeling. For 
cysteine-rich proteins, this means mutations of native cysteines to serine or alanine, and 
mutation to introduce new cysteine as the labeling site. For instance, intracellular domain 
of EGFR contains six native cysteines in kinase domain and three cysteines in C-terminal 
tail. The complex cysteine mutation combination is not only time-consuming but also 
possibly impairing protein activity and stability. Furthermore, natural cysteines may play 
crucial roles structurally or functionally, such as facilitating protein folding by forming 
disulfide bridges, or functioning as the catalytic residue in cysteine protease. Cysteine 
residues as such are simply untouchable during the mutagenesis, thus posing a challenge 
for EPR spin labeling. Alternatively, one could introduce unnatural amino acid (UAA) as 
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the labeling site, such as p-acetylphenylalanine (Young et al., 2010). However, this 
approach so far is mainly applied in E.coli expression system, while for target protein like 
EGFR, only eukaryotic cell culture is acceptable for appropriate expression. In addition, 
mutagenesis is still required, of which the effect on protein expression, folding and activity 
is unknown. IDSL, on the other hand, rests upon the high affinity of available inhibitors 
towards wildtype protein, so no mutation is necessary.  Another benefit of IDSL is that a 
sizeable number of inhibitors have already been commercialized and well characterized, 
which is convenient for repurposing them as EPR spin labels. For example, protein kinase 
inhibitor has become hotspot for pharmaceutical development since the approval of 
Fasudil for cerebral vasospasm in Japan in 1995 (reviewed by Fabbro et al., 2015; 
Shibuya and Suzuki, 1993). Protein kinases play such a pivotal role in cell signaling 
pathway that their overexpression and overactivation are often linked to various cancer 
conditions, which makes kinase inhibitor one of the intensively investigated branches of 
anticancer therapeutics. So far, there are more than 250 candidate kinase inhibitors in 
clinical development (Klaeger et al., 2017), with many among them already cocrystallized 
with target kinases. These kinase-inhibitor complex structures provide molecular details 
about interaction mode which facilitate inhibitor-based spin label design from many 
perspectives, such as considering where to attach spin label on the inhibitor, and 
evaluating theoretical interspin distance. EGFR studied in this thesis project is one such 
research hotspot. With the rich collection of crystal structures and publications about 
EGFR inhibitors, it is convenient to initiate IDSL for PELDOR. Also, covalent inhibitor is 
preferred for IDSL application, because irreversible binding eliminates the possibility of 
spin label being washed off during the subsequent purification steps. However, if the 
affinity of noncovalent inhibitor is within nanomolar range, labeling procedure with limited 
washing step could be tolerated. Additionally, IDSL is not confined to the conformation 
study of kinases. Instead it can be broadly applied to available covalent inhibitors against 
many protein families, such as omeprazole (Prilosec, AstraZeneca) against H+/K+ ATPase 
and clopidogrel (Plavix, BMS/Sanofi) against P2Y12 receptor (reviewed by Singh et al., 
2011). Furthermore, it should be mentioned that covalent IDSL is the extension of a more 
general concept, namely, affinity labeling. It is originally applied to enzyme or antibody 
labeling, where noncovalent binding moiety of the probe is attracted to catalytic pocket, 
followed by reaction moiety attacking the nucleophilic side chain of an amino acid, leading 
to irreversibly modifying protein with fluorophore or radioactive label. By labeling amino 
acids nearby with different affinity labels, activity sites of the enzyme and antibody were 
identified and mapped (Wofsy et al., 1962). Applications of affinity labeling as such can be 
searched for and easily repurposed for PELDOR labeling. Here in this thesis, the idea of a 
fluorescent affinity label (Blair et al., 2007) is borrowed and converted for EPR purpose, in 
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which amino acid near the ATP-binding site (C773) was specifically labeled by nitroxide 
spin.  
Despite of the benefits in PELDOR study, IDSL is not without its limitation. In previous 
section, effects of PDsl over conformational equilibrium of EGFR has been discussed, 
with alternatives proposed and discussed. In general, influence of inhibitor over protein 
structure and oligomerization should be carefully investigated before designing inhibitor-
based spin label.  Additionally, PELDOR is limited to intermolecular distance 
measurement, if each protein molecule has only one binding site for the inhibitor. To 
achieve intramolecular measurement with IDSL, second labeling site on the same protein 
has to be established. If the protein of interest contains few natural cysteine residues, 
conventional SDSL can be combined with IDSL for the protein labeling. Likewise, UAA-
based labeling should be considered when target protein is  compatible with its workflow. 
If the protein contains multiple domains, inhibitors targeting other domains serve as the 
natural candidates for second label. For some proteins with paramagnetic cofactors such 
as Cu2+, metal ions can be utilized to measure ion-nitroxide distance in PELDOR (Abdullin 
et al., 2015). Another concern with monolabeling of protein by IDSL is that monomeric 
protein, one basic ingredient of oligomerization equilibrium, is missing in the final 
PELDOR results, which is unfortunate for conformational study involving protein 
oligomerization. This lack of monomer information could be remedied by combining 
analytical gel filtration assay to characterize protein oligomerization status. If possible, 
size exclusion chromatography equipped with multi-angle light scattering (MALS) 
detectors would even measure molecular weights of eluted species in gel filtration. 
However, it is not guaranteed that the size exclusion column can thoroughly resolve 
different oligomeric species, as noticed in the EGFR study. In that case, it is difficult for 
MALS analysis to calculate molecular weight from a mixed gel filtration peak. Moreover, 
during drug development, candidate compound could hit more than one targets, a 
phenomenon termed as polypharmacology (reviewed by Reddy and Zhang, 2013). This 
off-target effect also poses a challenge for IDSL to be further applied in in-cell PELDOR, 
where inhibitor specificity is demanded to selectively label the target in the surroundings 
full of miscellaneous proteins. Although EGFR inhibitors have already shown high 
selectivity in chemical proteomics study, it is not generally the case for other tyrosine 
kinase inhibitors (Klaeger et al., 2017). Therefore, more careful literature research on 
inhibitor specificity is recommended before starting new inhibitor-based spin label design 
for in-cell PELDOR.  
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4.5 ICD, Sec7, calmodulin and lipid: a tale of four  
In section 3.2, MST is successfully applied to protein interaction study of EGFR. Emerging 
evidence from current study has repeatedly shown that ARNO-Sec7 domain binds to JM 
segment of EGFR-ICD. In the meantime, it is confirmed that calmodulin interacts with the 
very same JM segment in a Ca2+-dependent manner, and that it effectively competes with 
Sec7 for JM binding. Yet the story did not end there. The fruitful collaboration with NMR 
group of Manuel Etzkorn brings some intriguing insights into Sec7:JM interaction, with the 
role of lipid also clarified. A tale of four has gradually unfolded.  
The NMR data of Sec7 and JM peptide was collected and analyzed by Dr. Manuel 
Etzkorn and Dr. Aldino Viegas. Not only do they confirm Sec7:JM interaction, but also 
identify key residues involved in this interaction. In the titration assay of Sec7 with JM, 
concentration of 15N-labeled Sec7 was maintained constantly at 60μM while concentration 
of unlabeled JM varied from 0 to 420μM. 1H-15N HSQC spectra were acquired, after which 
combined chemical shift changes were aligned with Sec7 sequence to map amino acids 
relevant to the binding. Based on the chemical shift perturbations upon JM binding, 
involved residues are highlighted as dark green in Figure 4.9.  
 
Figure 4.9 Affected residues on ARNO-Sec7 due to Sec7:JM interaction. Crystal structure of 
ARNO-Sec7 (PDB ID: 4JMI; Rouhana et al., 2013) is depicted as grey cartoon. Amino acids with 
major changes of combined chemical shift are colored dark green. Helices are denoted 
alphabetically according to Mossessova et al., 1998. Figure was prepared based on data from 
Aldino Viegas.   
Interestingly, these amino acids partially overlap with the binding site of Arf1 (Cherfils et 
al., 1998; Mossessova et al., 1998; Renault et al., 2003). Especially, αH-helix is a major 
part of the binding site for both Arf1 and JM, and is covered by Sec7-PH linker and C-
terminal helix in autoinhibited ARNO. Deletion of PBR in ARNOΔPBR relieves the 
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autoinhibition mechanism and thus opens the binding site for Arf1 docking (DiNitto et al., 
2007). The masking of αH-helix in autoinhibited state and exposure of it in open state, fit 
well with MST data in section 3.2.3.1, where ARNOΔPBR shows binding towards EGFR-
ICD while ARNO not. Furthermore, when four residues on the hydrophobic patch of αH-
helix are collectively mutated into alanines, the binding capacity of Sec7 towards JM or 
ICD is lost in MST assay. This is also in agreement with NMR data, and further supports 
the mapping results from HSQC.  
Meanwhile, titration assay of JM with Sec7 was also performed, with 15N-labeled JM at 
40μM and unlabeled Sec7 varying from 0 to 280μM. 1H-15N HSQC spectra locate major 
chemical shift perturbations to the N-terminus of JM segment, i.e. JM-A. Since JM-A is 
rich in basic residues (8 arginine residues and 1 lysine residue) that are positively charged 
at physiological pH, question has been raised that whether Sec7:JM interaction could be 
purely caused by electrostatic attraction between JM-A and negatively charged surface of 
Sec7. Therefore, a scrambled version of JM with random sequence, JMsc, was also 
tested via 1H-15N HSQC, where JMsc in the presence of three-fold excess of Sec7 shows 
no chemical shift change. This corroborates the MST data in section 3.2.3.3, and indicates 
that Sec7:JM interaction is sequence-dependent.  
As a known EGFR modulator, calmodulin also recognizes JM segment upon activation 
(Aifa et al., 2002; Martín-Nieto and Villalobo, 1998). In this thesis project, calmodulin:JM 
interaction has been confirmed by both MST and NMR. Data acquired from NMR reveal 
that the affected area upon calmodulin binding is JM-A segment, practically identical to 
the one in Sec7 interaction. Additionally, it is indicated by NMR that calmodulin:JM 
interaction is stronger than Sec7:JM, which supports the similar observation from MST 
assay and explains the efficiency of calmodulin in competition assay (see section 3.2.4.2).   
However, Sec7 and calmodulin are not the only factors at play. Acidic (or anionic) 
phospholipid at the inner leaflet of plasma membrane has also been shown to interact with 
basic JM segment (Aifa et al., 2002; Sato et al., 2006; Sengupta et al., 2009). To evaluate 
anionic lipid interaction with JM, and to compare it with Sec7:JM or calmodulin:JM 
interaction, an in vitro lipid bilayer system, i.e. nanodisc was introduced in the NMR study. 
Two types of phospholipids were utilized to study the effect of net charge on JM:lipid 
interaction, namely neutral phospholipid POPC and anionic phospholipid POPS. Nanodisc 
assemblies with 100% POPC and 70% POPC + 30% POPS were compared, which 
shows that only anionic phospholipid-containing nanodisc induces chemical shift 
perturbations on JM resonance. Moreover, residues with significant perturbations are from 
JM-A segment again. Interestingly, lipid:JM interaction is strengthened once the negative 
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charge density on nanodisc is increased by using 50% anionic phospholipid, confirming 
the electrostatic nature of this interaction. Notably, the exact JM region perturbed by lipid 
is slightly shorter than those by calmodulin and Sec7, with E661-E666 not affected upon 
lipid binding. This difference was conveniently exploited to study the competition between 
lipid and Sec7 for JM binding. When mixture of JM and nanodisc with 50% POPC + 50% 
POPS was combined with Sec7, distinct chemical shift perturbations of E661-E666 were 
observed and they are consistent with the perturbations from Sec7:JM interaction. 
Although Sec7 could not fully shift the binding equilibrium from lipid:JM towards Sec7:JM, 
this still indicates that Sec7 is capable of interacting with JM in the proximity of nanodisc 
with a high content of anionic phospholipids. Additionally, although ICD:Sec7 interaction 
seems quite weak according to MST data, ICD:ARNOΔPBR shows four-fold stronger 
binding affinity (Kd of 49.2μM vs. 12.5μM). The unclear origin of this additional affinity 
requires further investigation in future. Nevertheless, it means that ARNO, once relieved 
from its autoinhibition, has the potential of binding to EGFR with a reasonable affinity. 
Furthermore, it has been shown that EGFR cluster overlaps with PIP2 cluster on cell 
membrane (Wang et al., 2014). Since PIP2 could enrich ARNO in membrane proximal 
region through its recognition of ARNO-PH domain (reviewed by Kolanus, 2007), local 
concentration of ARNO is increased, which further promotes ARNO interaction with 
EGFR-ICD. Taken together, these data add more credit to the physiological relevance of 
Sec7:JM interaction at plasma membrane.  
4.6 Physiological implication of Sec7:ICD interaction 
So far the story has been told around two main characters, namely Sec7 and ICD, yet it is 
not fully understood in what way the Sec7:ICD interaction is relevant to EGFR regulation 
under physiological conditions. EGFR has long been known to play a key role in cell 
growth, proliferation and migration, and its upregulation is frequently involved in non-small 
cell lung cancer (reviewed by Soria et al., 2012), breast cancer (reviewed by Masuda et 
al., 2012) and colorectal cancer (reviewed by Markman et al., 2010). Meanwhile, ARNO 
overexpression has also been reported in human colorectal adenocarcinoma, and it 
correlates with increased EGFR signal (Pan et al., 2014). Also, SecinH3-treated lung 
cancer cells show reduced EGFR signaling and inhibited proliferation (Bill et al., 2012). 
Therefore, it is reasonable to connect Sec7:ICD interaction to EGFR overactivation and 
carcinogenesis. Here two hypotheses are proposed concerning the potential role(s) 
played by ARNO in EGFR signaling.   
The first hypothesis, dubbed as “endocytosis hypothesis”, is based upon several 
observations from other studies: (1) phosphorylated EGFR can recognize and activate 
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GEP100, which in turn activates Arf6 as its specific GEF and induces invasion of tumor 
cells (Morishige et al., 2008; Sabe et al., 2009). (2) Activated Arf6 can recruit ARNO onto 
plasma membrane via Arf6-PH interaction and facilitates relieving the autoinhibition 
mechanism of ARNO (Cohen et al., 2007; Stalder et al., 2011). (3) Activated Arf6 
regulates plasma membrane/endosome trafficking via clathrin-independent or clathrin-
dependent pathway (reviewed by D’Souza-Schorey and Chavrier, 2006). (4) During 
endocytosis, activated EGFR can maintain long-lived signaling in early endosome 
(reviewed by Murphy et al., 2009; reviewed by Villaseñor et al., 2016; Tomshine et al., 
2009; Wang et al., 2002), a phenomenon known as “endosomal signaling”. Thus upon 
EGF stimulation, EGFR-GEP100-Arf6 cascade is triggered. Arf6, which is activated as 
Arf6-GTP, recruits and activates ARNO which directly interacts with EGFR on its  JM 
segment. Subsequently, Arf6-GTP mediates endocytosis which through its ARNO 
connection carries EGFR as well. Internalized EGFR is harbored in endosome vesicles, 
and continues promoting downstream signaling pathways. Notably, similar model has 
been applied to Wnt/β-catenin pathway, where Wnt-induced Arf6 activation drives 
internalization of c-Met, also a receptor tyrosine kinase, which in signaling endosome 
further mediates downstream signaling to ERK and increases cytoplasmic β-catenin 
(Pellon-Cardenas et al., 2013). However, for EGFR, it is still in question whether signaling 
from endosome is more potent than that from plasma membrane. Therefore, endocytosis 
hypothesis should be tested, e.g. via mutagenesis and pharmacological approaches. The 
former approach involves mutants such as dominant-negative GDP-bound Arf6(T27N) 
and constitutively active GTP-bound Arf6(Q67L). The latter approach involves compounds 
such as SecinH3, a GEF inhibitor targeting Sec7 domain. Effects of Arf6 or ARNO on 
EGFR endocytosis and signaling can be evaluated via cellular assay by comparing EGFR 
autophosphorylation, internalization and downstream signaling between Arf6 mutants and 
wildtype Arf6, or between SecinH3-treated cells and DMSO-treated cells. 
Considering the critical function of JM in EGFR allosteric activation (Jura et al., 2009; Red 
Brewer et al., 2009), it is reasonable to postulate that Sec7:JM interaction might play a 
role more direct than mere “middle man” in Arf6-orchestrated endocytosis. The inspiration 
for second hypothesis, named “priming hypothesis”, comes from electrostatic engine 
model suggested as EGFR activation mechanism (McLaughlin et al., 2005). During early 
days of research, calmodulin was claimed to inhibit EGFR activity, based on detergent-
solubilized EGFR sample purified via calmodulin affinity chromatography (BENGURÍA et 
al., 1995; San Jose et al., 1992). However, recent data based on living cells have shown 
the activating role of calmodulin, which is confirmed by multiple studies (Li et al., 2004, 
2012; McLaughlin et al., 2005; Sengupta et al., 2007). To explain this activating function, 
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Stuart McLaughlin proposed electrostatic engine model. According to this model, during 
resting phase, positively charged parts of JM and kinase domain are tethered to plasma 
membrane, where the inner leaflet contains anionic phospholipid such as PS or PIP2, and 
this electrostatic interaction impedes free movement of JM and kinase domain for EGFR 
activation. Upon EGF stimulation, calmodulin is activated via PLCγ and phospholipase A2 
(reviewed by Sánchez-González et al., 2010), and by directly binding to JM, the negatively 
charged calmodulin (pI 4.09) reverses the charge on JM. Newly formed calmodulin:JM 
complex is repelled by anionic phospholipid in the proximity. Both JM and kinase domain 
fall off the plasma membrane, which allows them to rearrange into active conformation 
(McLaughlin et al., 2005).  
The priming hypothesis assumes a similar role for ARNO-Sec7 in EGFR activation. 
However, the difference is that JM-binding affinities of Sec7 and ARNOΔPBR are weaker 
than calmodulin, and it has been shown by NMR that Sec7 can only partially pull JM out of 
the nanodisc, so Sec7 alone probably cannot fulfil full function as an EGFR activator in 
this model. Therefore, it is further postulated that Sec7 binds to JM prior to calmodulin 
binding. Sec7 binding releases JM partly from plasma membrane, and thereby primes it 
for subsequent calmodulin binding and full release from lipid environment, hence the 
name “priming” for this hypothesis. However, it is unclear in cells whether Sec7-binding 
actually happens before calmodulin-binding event. Studies have shown that after EGF 
stimulation the peaking time of cellular free Ca2+ varies between 1 and 3min (Hughes et 
al., 1991; Nojiri and Hoek, 2000; Uyemura et al., 2005), whereas the peaking time for 
Arf6-GTP is 30sec (Boulay et al., 2008). However, the locality of Ca2+ signaling, due to its 
steep concentration gradient around Ca2+ pool (Clapham, 2007), hinders reliable 
estimation of the time needed for calmodulin activation in the proximity of plasma 
membrane. Also, the time for Arf6-GTP to recruit and activate ARNO is not accounted for 
in the study. Therefore, this comparison based on literature is inconclusive. Additionally, it 
is possible that on plasma membrane there is pre-bound ARNO independent of EGF 
stimulation, such as ARNO enriched by PIP2 cluster as mentioned in previous section. In 
that case, ARNO can function as a priming modulator as well. Practically, priming 
hypothesis can be verified as follows. First, the role of Sec7 in electrostatic engine model 
could be verified by using nanodisc containing full length EGFR. Effects of Sec7 over 
EGFR activity are then compared between controls with varying anionic lipid compositions 
in nanodisc or salt concentrations in buffer, since these factors influence the electrostatic 
attraction. Second, to investigate the priming role of ARNO, it should be examined 
whether calmodulin activation of EGFR depends on ARNO. To serve this purpose, 
chemical inhibition of ARNO-Sec7 via SecinH3 treatment or gene silencing via RNAi (RNA 
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interference) could be utilized to suppress ARNO-Sec7 function or expression in cells. 
Thereafter, comparison of the calmodulin activation effects between SecinH3-/RNAi-
treated and untreated cells will reveal whether ARNO renders EGFR activatable to 
calmodulin, i.e. whether there is a priming effect.  
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5 Materials and Methods 
5.1 Materials 
5.1.1 Equipment 
Name Manufacturer 
ÄKTA FPLC/Pure/avant GE Healthcare 
Analytical balance CPA324S Sartorius 
Autoclave VX-150 Systec 
Balance BL 1500S Sartorius 
BioSpectrometer Eppendorf 
Block heater Stuart Equipment 
Blotting paper Macherey-Nagel  
Centrifuge 5417C Eppendorf 
Centrifuge 5427 R Eppendorf 
Centrifuge 5430 Eppendorf 
Centrifuge 5804 R Eppendorf 
Centrifuge Multifuge 3 S-R Heraeus Thermo Fisher Scientific 
Chromatography cooling cabinet UNICHROMAT 1500 “PRO” UniEquip 
Desalting column HiPrepTM 26/10  GE Healthcare 
Electrophoresis chambers BIO-RAD 
Electrophoresis power supply E802/E865 CONSORT 
French press cell disrupter Thermo Fisher Scientific 
High-speed centrifuge Avanti J-26S XP  Beckman Coulter 
High-speed centrifuge tube NalgeneTM Oak Ridge for JA-25.50 Thermo Fisher Scientific 
Incubation shaker Multitron Cell INFORS HT 
Incubator Heraeus HERAcell 240 Thermo Fisher Scientific 
Incubator HerathermTM  Thermo Fisher Scientific 
Incubator shaker InnovaⓇ 40 New Brunswick Scientific 
Incubator shaker InnovaⓇ 42 New Brunswick Scientific 
JA-25.50 Rotor Fixed-Angle Beckman Coulter 
JLA-8.1000 Rotor J-LITEⓇ Fixed-Angle Beckman Coulter 
Magnetic stirrer IKAMAGⓇ IKA 
Monolith NT.115 NanoTemper 
Multi-Axle Roller-Mixer RM5-30V neoLab 
MultipetteⓇ M4 Eppendorf  
MultipetteⓇ plus Eppendorf  
Odyssey Imaging System LI-COR 
Orbital shaker KS501 digital IKA 
Overhead tumbler PTR-30 Grant-bio 
Peristaltic pump 2115 Multiperpex LKB Bromma 
Materials and Methods 
 
 71 
pH meter FiveEasyTM METTLER TOLEDO 
Pipette controller accu-jetⓇ pro BRAND 
Pipette ResearchⓇ plus Eppendorf  
Plate reader InfiniteⓇM1000 PRO Tecan 
Polypropylene Bottle Assembly for JLA-8.1000 Beckman Coulter 
SDS-PAGE gel casting stands/frames/combs BIO-RAD 
SEC column HiLoadTM 16/600 SuperdexTM 200 pg GE Healthcare 
SEC column HiLoadTM 16/600 SuperdexTM 30 pg GE Healthcare 
SEC column HiLoadTM 16/600 SuperdexTM 75 pg GE Healthcare 
SEC column SuperdexTM 200 10/300 GL GE Healthcare 
Semi-dry blotter“Pegasus” PHASE 
Semi-dry transfer cell TRANS-BLOTⓇ SD BIO-RAD 
Spectrophotometer NanoDrop 2000c Thermo Fisher Scientific 
Thermomixer HLC 
Thermomixer comfort Eppendorf 
Vibra-CellTM Ultrasonic Liquid Processor VCX400 Sonics & Materials 
Vortex 4 basic IKA 
Water bath GFLⓇ 
Water Purification System BarnsteadTM MicroPureTM Thermo Fisher Scientific 
 
5.1.2 Chemicals and reagents 
Name  Supplier   
Acetic acid, ROTIPURANⓇ 100%, p.a. Carl Roth 
Acrylamide/Bis-solution(37.5:1) RotiphoreseⓇ Gel 30 Carl Roth 
Adenosine 5’-triphosphoric acid disodium salt, ≥ 98% PanReac AppliChem 
AEBSF SERVA 
Alexa FluorTM 647 NHS Ester  Thermo Fisher Scientific  
APS, ≥ 98%, p.a., ACS Carl Roth 
Bestatin  SERVA 
Calcium chloride, ≥ 98%, dehydrated, powder Carl Roth 
CoomassieⓇ Brilliant Blue G 250  SERVA 
d-Desthiobiotin, ≥ 98%(TLC) Sigma-Aldrich 
D(+)-Maltose monohydrate, ≥ 95%, for biochemistry Carl Roth 
Deuterium oxide, 99.8 atom% D, D2O Sigma-Aldrich 
Dimethyl sulfoxide, 99.9+%, ACS reagent, ACROS OrganicTM Thermo Fisher Scientific  
DPBS, no calcium, no magnesium, gibcoⓇ Thermo Fisher Scientific  
DTT, ≥ 99%, p.a. Carl Roth 
E-64 SERVA 
EDTA, p.a. PanReac AppliChem 
EGTA, ≥ 99%, p.a. Carl Roth 
Ethylene glycol-d6 99% Deutero 
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Gel Filtration Markers Kit MWGF1000 Sigma-Aldrich 
Glycerol, ROTIPURANⓇ ≥ 99.5%, p.a., anhydrous Carl Roth 
Glycine, PUFFERANⓇ ≥ 99%, p.a. Carl Roth 
Guanosine 5’-diphosphate sodium salt, ≥ 96% (HPLC) Sigma-Aldrich 
Guanosine 5’-triphosphate sodium salt hydrate, ≥ 95% 
(HPLC) 
Sigma-Aldrich 
HEPES, Buffer grade PanReac AppliChem 
Hydrochloric acid 37% AnalaR NORMAPURⓇ VWR Chemicals 
Imidazole PanReac AppliChem 
IPTG, 99% Carbolution 
Kanamycin sulphate, ≥ 750 I.U./mg Carl Roth 
LB Broth (Lennox) for molecular biology Carl Roth 
Magnesium chloride Hexahydrate, ≥ 99.0%, p.a. Fluka  
Monolith Protein Labeling Kit Red-NHS 2nd Generation NanoTemper  
PD168393, ≥ 98% (HPLC) Sigma-Aldrich 
PD168393sl (PDsl) Synthesized by Jeffrey Hannam 
Phosphoramidon SERVA 
PierceTM Centrifuge Columns and Caps, 10mL Thermo Fisher Scientific  
Protein Ladder, PageRulerTM Plus, prestained Thermo Fisher Scientific 
SDS, grained pure PanReac AppliChem 
Sodium chloride, ≥ 99.5%, p.a., ACS, ISO Carl Roth 
Sodium hydroxide, ≥ 98%, p.a., ISO, in pellets Carl Roth 
Sodium orthovanadate PanReac AppliChem  
TEMED, ≥ 99%, p.a., for electrophoresis Carl Roth 
TES, PUFFERANⓇ ≥ 99% Carl Roth 
TRIS, PUFFERANⓇ ≥ 99.9%, ultra quality Carl Roth 
TritonⓇ X-100 PanReac AppliChem 
TweenⓇ 20  PanReac AppliChem 
β-Mercaptoethanol, Molecular biology grade PanReac AppliChem 
 
5.1.3 Consumables 
Name  Manufacturer 
Amylose Resin NEB 
Assay plate 96-well, Half Area, Black Flat Bottom, Non-Binding 
Surface Corning 
Blotting paper Macherey-Nagel 
Capillaries for MST, MonolithTM NT.115, premium NanoTemper 
Centrifugal concentrator VivaspinⓇ Turbo 15 Sartorius  
Centrifugal Filter, AmiconⓇ Ultra 0.5mL Merck Millipore 
Centrifugal Filter, AmiconⓇ Ultra 4 Merck Millipore 
Combitips advancedⓇ Eppendorf  
Disposable cuvette, RotilaboⓇ, Polystyrene  Carl Roth 
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Disposable Syringe 5/10mL DiscarditTMⅡ BD 
NAP-5 disposable columns, illustraTM GE Healthcare 
Ni-NTA Agarose ProtinoⓇ Macherey-Nagel 
Nitrile Gloves StarGuardⓇ Comfort STARLAB 
Nitrocellulose Blotting Membrane AmershamTM ProtranTM 
premium 0.45μm GE Healthcare 
Protein LoBind Tube 1.5mL Eppendorf  
Reaction tube, SafeSeal 1.5mL/2mL, Polypropylene Sarstedt  
Serological pipette, CostarⓇStripetteⓇ  Corning  
Sf-900TM III Serum Free Medium gibcoⓇ Thermo Fisher Scientific  
Single-use hypodermic needles, StericanⓇ B.Braun 
Strep-TactinⓇSuperflowⓇ high capacity resin IBA Lifesciences 
TSK SUPRA Hypodermic Needles 2.00×100mm TSK 
Tube 15mL,120×17mm, Polypropylene Sarstedt 
Tube 50mL,114×28mm, Polypropylene Sarstedt 
 
5.1.4 Enzymes and proteins 
Name Supplier    
BSA Fraction V, lyophilized  PAN-Biotech 
BSA, ≥ 98%, lyophilized  Sigma-Aldrich 
His-tagged NΔ17Arf1 In-house production by Volkmar Fieberg  
His-tagged TEV protease In-house production by Volkmar Fieberg 
His-tagged YopH (protein tyrosine phosphatase)  In-house production by Volkmar Fieberg  
Human EGF, recombinant from E.coli, lyophilized PeproTech  
 
5.1.5 Antibodies 
Name  Dilution Species Supplier   Catalog # 
Anti-EGFR(D38B1) monoclonal 1:1000 Rabbit Cell Signaling 4267S 
Anti-EGFR(F4) monoclonal 1:1000 Mouse Santa Cruz sc-53274 
Anti-MBP monoclonal 1:10000 Mouse NEB E8032S 
Anti-mouse IgG (H+L) DyLightTM800 1:15000 Goat Cell Signaling 5257S 
Anti-rabbit IgG (H+L) IRDyeⓇ800CW 1:15000 Donkey LI-COR 926-32213 
p-Tyr(PY99) pY monoclonal 1:5000 Mouse Santa Cruz sc-7020 
Phospho-EGFR(Tyr992) pY992 polyclonal 1:1000 Rabbit Cell Signaling 2235S 
Streptavidin IRDyeⓇ800CW(no antibody) 1:10000 — LI-COR 926-32230 
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5.1.6 Bacteria strains and cell lines 
Strain Genotype Provider   
E.coli BL21(DE3) 
fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS 
λ DE3 = λ sBamHIo ∆EcoRI-B 
int::(lacI::PlacUV5::T7 gene1) i21 ∆nin5 
Merck Millipore 
E.coli NEBⓇ10-beta  
Δ(ara-leu) 7697 araD139  fhuA ΔlacX74 
galK16 galE15 e14-  Φ80dlacZΔM15  recA1 
relA1 endA1 nupG  rpsL (StrR) rph 
spoT1 Δ(mrr-hsdRMS-mcrBC)  
NEB 
E.coli DH10MultiBacTurbo 
F– mcrA Δ(mrr-hsdRMS-mcrBC) 
Ф80lacZΔM15 ΔlacX74 recA1 endA1 
araD139 Δ(ara, leu)7697 galU galK λ– rpsL 
nupG /pMON14272 v-cath::Ampr chiA::LoxP 
*/ pMON7124  
ATG:biosynthetics 
Spodoptera frugiperda Sf9 Derived from IPLB-Sf21-AE Thermo Fisher Scientific 
 
5.1.7 Constructs  
Name Vector Antibiotic Expression host Tag  
Cleavage 
site 
EGFRΔC pACE-Bac1 Gm Sf9 SBP TEV 
HTint-ICDΔJM27 pACE-Bac1 Gm Sf9 His  Factor Xa/TEV 
MBPT-ICD pACE-Bac1 Gm Sf9 MBP TEV 
MBPT-ICD998 pACE-Bac1 Gm Sf9 MBP TEV 
MBPT-ICD998(4CSA 
S744C)  pACE-Bac1 Gm Sf9 MBP TEV 
MBPT-ICD998(I682Q)  pACE-Bac1 Gm Sf9 MBP TEV 
MBPT-ICD998(V924R)  pACE-Bac1  Gm Sf9 MBP TEV 
HT-ARNO pET28 Kan E.col i  His TEV 
HT-ARNO-PH pET28 Kan E.col i  His  TEV 
HT-Sec7 pET28 Kan E.col i  His  TEV 
HT-Sec7-4A pET28 Kan E.col i  His  TEV 
HT-ARNOΔPBR pET28 Kan  E.col i  His TEV 
HT-Calmodulin  pET28 Kan E.col i  His TEV 
MBPT-JM pET28 Kan  E.col i  MBP TEV 
MBPT-JMsc pET28 Kan E.col i  MBP TEV 
HT-ICD pFastBac1 Amp/Gm Sf9 His  TEV 
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5.1.8 Software 
Name Provider  
Affinity Designer 1.6.1 Serif (Europe) Ltd. 
ChemDrawⓇ17.1.1.0(1) PerkinElmer Informatics, Inc. 
DataGraph 4.3 Visual Data Tools, Inc. 
GraphPad PrismⓇ7.0a GraphPad Software, Inc. 
i-controlTM Tecan Group, Ltd.  
Image StudioTM Lite LI-COR, Inc. 
MO.AffinityAnalysis 2.3.0.7385 NanoTemper Technologies GmbH 
PyMOL Molecular Graphics System Schrödinger, LLC. 
SnapGeneⓇ4.2.4 GSL Biotech LLC. 
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5.2 Methods 
5.2.1 Protein expression 
All the ARNO-related constructs, calmodulin and JM/JMsc constructs were expressed in 
prokaryotic E.coli system. In contrast, all the EGFR-related constructs except JM/JMsc 
were expressed in eukaryotic Sf9 system. Notably, before large-scale protein production, 
small test expression and “quick and dirty” purification (see section 5.2.2.1) were routinely 
conducted to examine protein expression level. 
5.2.1.1 Protein expression in E.coli system 
Protein expression in E.coli is summarized as follows:  
Table 5.1 Overlook of protein expression 
Protein  Resistance OD600 before IPTG Expression conditions  
HT-ARNO Kan 0.6-0.8 250μM IPTG, 4h @37℃	
HT-ARNO-PH Kan 0.6-0.8 250μM IPTG, 4h @37℃ 
HT-Sec7 Kan 0.6-0.8 250μM IPTG, 4h @37℃ 
HT-Sec7(4A) Kan 0.6-0.8 250μM IPTG, 4h @37℃ 
HT-ARNOΔPBR Kan  0.2-0.3 100μM IPTG, overnight @20℃ 
HT-Calmodulin Kan 0.6-0.8 250μM IPTG, 4h @37℃ 
MBPT-JM Kan  0.2-0.3 100μM IPTG, overnight @20℃ 
MBPT-JMsc Kan 0.2-0.3 100μM IPTG, overnight @20℃	 
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Part of protein expression work in E.coli system was assisted by Volkmar Fieberg. To start 
with, E.coli preculture was initiated in 20mL LB medium (50μg/mL Kanamycin) via 
inoculation of BL21(DE3) glycerol stock of different constructs. After overnight incubation 
at 37℃ with 110RPM shaking, the preculture was transferred to 2L LB medium with 
50μg/mL Kanamycin to start large culture. The cells grew further at 37℃ until reaching 
target “OD600 before IPTG” (see table above), followed by IPTG addition. The large 
cultures were kept in incubation shaker with 110RPM shaking, under corresponding 
“expression conditions” (see table above). In the end, cells were harvested in Beckman 
high-speed centrifuge with JLA-8.1000 Rotor at 4℃,4000RPM for 20min. Supernatant 
was discarded and pellets were deposited in -80℃ freezer until purification.   
5.2.1.2 Protein expression in Sf9 system 
Sf9 cell maintenance and protein expression were done by Yvonne Aschenbach. The Sf9 
system used in the lab is MultiBacTurbo modified from Bac-to-BacⓇ system. Briefly, the 
recombinant donor plasmid (pFastBac1 or pACE-Bac1) containing cloned gene of interest 
was delivered via transformation into DH10MultiBacTurbo. After transposition and antibiotic 
selection, recombinant bacmids were extracted, followed by Sf9 cell transfection to 
produce V0 recombinant baculovirus. Viral stock was typically amplified for at least one 
more round to obtain V1 before protein expression.  
To start large-scale protein expression, Sf9 cell culture was maintained in Sf-900TM III 
Serum Free Medium until reaching cell density of 2×106cells/mL. Protein expression was 
initiated by infecting Sf9 cells with baculovirus stock at volume ratio 1000:1 (cell vs. virus). 
The culture volume was kept at maximum 30% of flask volume during the expression. 
After 72h incubation at 27℃ with 80RPM shaking, cells were harvested in Beckman high-
speed centrifuge with JLA-8.1000 Rotor at 4℃,1000g for 10min. Supernatant was 
discarded while cell pellets were deposited in -80℃ freezer until purification.  
5.2.2 Protein purification 
Before going through large-scale protein purification, a small-scale test purification was 
routinely performed to check whether target protein was properly expressed. Simplified 
and fast steps of this procedure, especially washing steps, lead to unclean elution 
samples visualized on SDS-PAGE gel, hence the name “quick and dirty” purification. 
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5.2.2.1 “Quick and dirty” test purification 
Typically pellets from 30mL culture were taken as test purification material. Cell pellets 
were resuspended with 1mL lysis buffer (50mM Tris pH8 @4℃, 300mM NaCl, 10% 
Glycerol) in a 2mL reaction tube, followed by cell lysis on Vibra-CellTM Ultrasonic Liquid 
Processor. The sonification program is as follows: 1s working, 4s pause with 10 cycles 
and 30% power. During sonification, reaction tubes were sitting in the ice/water bath to 
keep samples cooled.  
After the lysis, cell debris was spinned down in a bench-top centrifuge: 20,000g for 5min 
@4℃. The supernatant was added to 100μL Ni-NTA or amylose resin slurry for incubation 
of 30min @4℃. Thereafter, the incubation mixture was transferred to a PierceTM 
Centrifuge Column connected to the peristaltic pump, followed by one round washing step 
with lysis buffer. Centrifuge column was disconnected, with bottom end sealed by the cap. 
Next, 50μL elution buffer (lysis buffer with 500Mm imidazole or 10mM maltose) was 
added for elution. Mixtures were incubated for 5min @4℃, followed by centrifugation to 
collect the eluted samples, which were subsequently analyzed via SDS-PAGE to check 
the protein expression levels. If they are too low, protein expression protocol should be 
improved. Otherwise, proceed to large-scale protein purification.  
5.2.2.2 Large-scale purification of soluble proteins 
Purification buffers:  
Lysis buffer Elution buffer 
50mM Tris pH 7.8 @4℃ 50mM Tris pH 7.8 @4℃ 
300mM NaCl 300mM NaCl 
10% glycerol 10% glycerol 
25mM imidazole 500mM imidazole or 10mM maltose 
  
Desalting buffer SEC buffer 
50mM Tris pH 7.8 @4℃	 20mM HEPES pH 7.8 @4℃ 
300mM NaCl 150mM NaCl 
25mM Imidazole  
 
In general, cells were disrupted via French press in lysis buffer supplemented with 
protease inhibitor cocktail. Lysate was cleared via high-speed centrifugation at 70,000g for 
20min, after which corresponding affinity chromatography purification (Ni-NTA- or 
amylose-based) was performed. Elution sample went through buffer exchange to switch 
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the buffer into desalting buffer, before TEV cleavage overnight at 4℃. Notably, during 
cleavage 14.3mM β-mercaptoethanol and 1mM EDTA were added. For all the His-tagged 
constructs, protein samples were subjected to reverse Ni-NTA chromatography, and flow-
through samples were concentrated to less than 5mL, followed by size exclusion 
chromatography in the appropriate columns (see table below). Thereafter, another 
concentration step was taken when necessary.  
Overlook of key facts in purification workflow is summarized here (see table below). 
General protocol has been modified to serve specific purposes. In addition to listed 
modifications, there have been the following changes. TEV cleavage of HT-ICD was done 
in the presence of 0.5μM His-tagged YopH and 0.5mM MgCl2 to dephosphorylate the 
kinase, and TEV cleavage of MBPT-JM and MBPT-JMsc was done at RT for 72h. For 
calmodulin purification, lysis buffer is 50mM HEPES pH 7.8 @4℃, 300mM NaCl, 10% 
Glycerol, 25mM imidazole. After French press, cleared lysate was heated at 80℃ for 
5min, then cooled down on ice for 10min, before centrifugation to remove denatured 
protein. Moreover, the protein sample was supplemented with 1mM CaCl2 right before 
SEC.  
Table 5.2 Overlook of protein purification workflow 
Protein Tag  TEV cleavage 
Reverse 
purification SEC columns  
EGFRΔC* SBP No No None 
HTint-ICDΔJM27 His  Yes  Yes  HiLoadTM 16/600 SuperdexTM 200 pg 
MBPT-ICD MBP No  No  HiLoadTM 16/600 SuperdexTM 200 pg 
MBPT-ICD998 MBP No  No  HiLoadTM 16/600 SuperdexTM 200 pg 
MBPT-ICD998(4CSA 
S744C)  MBP No  No  HiLoad
TM 16/600 SuperdexTM 200 pg 
MBPT-ICD998(I682Q)  MBP No  No  HiLoadTM 16/600 SuperdexTM 200 pg 
MBPT-
ICD998(V924R)  MBP No  No  HiLoad
TM 16/600 SuperdexTM 200 pg 
HT-ICD His  Yes  Yes  HiLoadTM 16/600 SuperdexTM 200 pg 
HT-ARNO His Yes Yes HiLoadTM 16/600 SuperdexTM 200 pg 
HT-ARNO-PH His  Yes Yes HiLoadTM 16/600 SuperdexTM 75 pg 
HT-Sec7 His  Yes Yes HiLoadTM 16/600 SuperdexTM 75 pg 
HT-Sec7(4A) His  Yes Yes HiLoadTM 16/600 SuperdexTM 75 pg 
HT-ARNOΔPBR His Yes Yes HiLoadTM 16/600 SuperdexTM 200 pg 
HT-Calmodulin  His Yes Yes HiLoadTM 16/600 SuperdexTM 75 pg 
MBPT-JM MBP Yes No HiLoadTM 16/600 SuperdexTM 30 pg 
MBPT-JMsc MBP Yes  No   HiLoadTM 16/600 SuperdexTM 30 pg 
* EGFRΔC was purified based on a different protocol which will be explained in next section. 
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5.2.2.3 Large-scale purification of membrane protein 
Unlike other constructs, EGFRΔC contains transmembrane segment, which means it 
cannot be purified with detergent-free buffer. Therefore, a customized membrane protein 
purification procedure was established.  
To begin with, cells were homogenized and lysed in Buffer A (50mM Tris pH8 @4℃, 
300mM NaCl, 10% Glycerol, 1mM EDTA and 1% TritonⓇ X-100), supplemented with 
protease inhibitor cocktail. The volume ratio between pellet and lysis buffer was 1:2, and 
lysis process took 1h with magnetic stirring in the ice/water bath. Thereafter, lysate went 
through centrifugation to remove the cell debris. The supernatant was diluted by five-fold 
with detergent-free buffer (Buffer A without TritonⓇ X-100). After incubation of supernatant 
with Strep-TactinⓇ	for 1h at 4℃, two rounds of washing were performed with wash buffer 
(same as Buffer A except that it has 0.1% TritonⓇ X-100). Then resin was transferred to a 
PierceTM Centrifuge Column connected to the peristaltic pump, and it was washed once 
more with D2O-containing Buffer B (100mm TES pH 7.8 @4℃, 300mM NaCl, 1mM EDTA, 
0.1% TritonⓇ X-100 in D2O) before elution with Buffer B plus 5mM Desthiobiotin. Eluted 
sample was concentrated with centrifugal filter (100kDa cutoff), until the volume reach 
100μL. Requirement of D2O-containing Buffer for PELDOR is explained in Results 
section.  
Because TritonⓇ X-100 has pronounced absorption at 280nm, concentration of EGFRΔC 
cannot be determined via NanoDrop. Instead, TritonⓇ X-100-dissolved EGFRΔC was 
quantified via western blot with anti-EGFR F4 antibody for detection, using another 
soluble EGFR protein as concentration standard. More details about western blot are in 
section 5.2.4.2, and protein concentration determination in section 5.2.4.3. 
5.2.3 Protein labeling 
Purified protein samples were labeled to serve the purpose of EPR measurement or 
fluorescence-based MST assay.    
5.2.3.1 Protein labeling by MTSL, PD168393 or PDsl 
Labeling of protein by MTSL or PDsl, which carries a nitroxide spin label, is suited to EPR 
spectroscopy. PD168393 labeling serves as a control in western blot to check whether 
spin label moiety impairs binding of the inhibitor towards EGFR kinase domain.  
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Labeling process was integrated into protein purification procedure. In general, protein 
concentrations in elution samples from affinity chromatography was measured via 
NanoDrop, and then labeling was immediately conducted by mixing certain amount of 
label under corresponding conditions (see table below). Thereafter, labeled samples went 
through SEC to isolate the target protein, which was rebuffered  into final D2O-containing 
buffer (100mM TES pH 7.8 @4℃, 150mM NaCl), followed by concentration and 
quantification via NanoDrop. Details of labeling procedure are summarized as follows: 
Table 5.3 Summary of protein labeling (A) 
Protein Label Protein: label molar ratio Labeling conditions 
MBPT-ICD998(4CSA 
S744C) MTSL 1:10 Dark, at 4℃, 2h 
EGFRΔC PDsl 1:1.1 Dark, on ice, 10min 
MBPT-ICD PDsl 1:2 Dark, on ice, 10min 
MBPT-ICD998 PD168393/PDsl 1:2 Dark, on ice, 10min 
MBPT-ICD998(I682Q)  PDsl 1:2 Dark, on ice, 10min 
MBPT-ICD998(V924R)  PDsl 1:2 Dark, on ice, 10min 
 
For EGFRΔC, a difference labeling procedure was followed. After the purification and 
concentration determination via western blot, protein was labeled by mixing with PDsl in 
1:1.1 molar ratio on ice for 10min.  
For PELDOR sample preparation, all proteins were mixed in 1:1 volume ratio with 
deuterated ethylene glycol, before being flash-frozen in Q-band PELDOR tubes.  
5.2.3.2 Protein labeling by fluorophores 
Fluorescent labeling was performed for MST assay. Theory and practice of MST will be 
introduced in section 5.2.6. The labeled constructs and labeling parameters are listed 
below: 
Table 5.4 Summary of protein labeling (B) 
Protein Dye Protein: dye molar ratio 
Labeling 
conditions 
Sec7 Alexa FluorTM 647 NHS Ester 1:10 Dark, on ice, 1h 
Sec7(4A) Alexa FluorTM 647 NHS Ester 1:10 Dark, on ice, 1h 
ICD RED-NHS 2nd generation 1:3 Dark, on ice, 0.5h 
ICDΔJM27 RED-NHS 2nd generation 1:3 Dark, on ice, 0.5h 
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Labeling reactions here are based on fluorophore NHS ester, which reacts with primary 
amine in the side chain of lysine. Reaction scheme is as follows: 
 
 
Figure 5.1 Reaction of NHS ester with primary amine on protein. Here 
R represents fluorophore, whereas P represents protein. Figure source: 
https://www.thermofisher.com/de/en/home/life-science/protein-
biology/protein-biology-learning-center/protein-biology-resource-
library/pierce-protein-methods/amine-reactive-crosslinker-
chemistry.html  
Labeling of Sec7 and Sec7(4A) requires mixing of 10μM protein with 100μM Alexa FluorTM 
647 NHS Ester in labeling buffer A (20mM HEPES pH7.8 @4℃, 150mM NaCl, 100mM 
NaHCO3). As for the labeling of ICD and ICDΔJM27, 10μM protein was mixed with 30μM 
RED-NHS 2nd generation in labeling buffer B (20mM HEPES pH7.8 @4℃, 150mM NaCl). 
Labeling mixtures were kept on ice in darkness for 0.5 or 1h (see table above), before 
being terminated by 100mM Tris (pH8 @4℃) as quencher. Next, samples were applied to 
pre-equilibrated (in labeling buffer B) illustraTM NAP-5 column to remove residual free dye, 
followed by elution with labeling buffer B. Protein concentration and DOL were determined 
on NanoDrop 2000c Spectrophotometer, after which labeled samples were aliquoted and 
flash-frozen in liquid nitrogen.   
5.2.4 Protein visualization and quantification 
Protein samples need to be characterized before downstream experiments. In this regard, 
SDS-PAGE and western blot are routinely conducted to examine the sample purity, 
phosphorylation level, etc., sometimes even in a quantitative way. Additionally, NanoDrop 
provides a fast yet relatively accurate approach to quantify protein concentration and in 
the case of labeled proteins, degree of labeling as well.  
5.2.4.1 SDS-PAGE analysis  
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is one of the 
fundamental methods to separate proteins. SDS is utilized as anionic detergent to unfold 
and coat protein uniformly. Unfolded protein carries the negative charges approximately in 
proportion to its size so different proteins can be separated via electrophoresis based on 
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sizes. The SDS-PAGE was performed according to Laemmli protocol (Laemmli, 1970). 
Buffers, solutions and gel casting procedures are shown below. Gel samples were 
prepared by mixing protein and loading buffer at volume ratio 5:1, followed by boiling on 
block heater for 10min. Gels were run at 200V for 45-50min, followed by gel staining and 
destaining. Thoroughly destained gels were scanned by LI-COR Odyssey imaging 
system.  
 
4 × Separating gel buffer 4 × Stacking gel buffer 
181.7 g/L Tris pH 8.8 @RT 60.6 g/L Tris pH 6.8 @RT 
4 g/L SDS 4 g/L SDS 
5 × Running buffer 6 × Loading buffer 
15.1 g/L Tris 7 mL 4x Stacking gel buffer 
72 g/L glycine 3 mL glycerol 
5 g/L SDS 1.5 g SDS 
 0.93 g DTT 
 1.2 mg bromophenol blue 
Staining solution Destaining solution 
150mL methanol 100mL acetic acid 
50mL acetic acid 900mL water 
300mL water  
0.5g CoomassieⓇ Brilliant Blue G  
 
Table 5.5 Gel casting setup 
 
Separating gel [%] Stacking gel [%] 
5.0 6.0 7.5 8.0 10.0 12.5 15.0 3.0 4.0 
Acrylamide 834 1000 1250 1333 1667 2083 2500 160 213 
Water 2878 2712 2462 2379 2045 1629 1212 1028 975 
Separating gel buffer 1250 — 
Stacking gel buffer — 400 
TEMED 8 2 
APS 30 10.4 
 
5.2.4.2 Western blot analysis 
Western blot analysis was performed based on the semi-dry blotting protocol from Kyhse-
Andersen (Kyhse-Andersen, 1984). All the buffers needed are shown below.  
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AnodeⅠbuffer AnodeⅡbuffer 
36.34 g/L Tris pH 10.4 @RT 3.03 g/L Tris pH 10.4 @RT 
Cathode buffer 10 × TBS 
3.03 g/L Tris pH 9.4 @RT 24.2 g Tris pH 7.6 @RT 
3 g/L Glycine 80 g NaCl  
After SDS-PAGE, gel was soaked in Cathode buffer, along with 3 pieces of blotting paper 
(C). Meanwhile, one piece of Nitrocellulose Blotting Membrane and one piece of blotting 
paper (B) were soaked in AnodeⅡ buffer, and another piece of blotting paper (A) was 
soaked in AnodeⅠ buffer. After 10min of soaking, stack the transfer unit in following 
orders: cathode/paper(C)/gel/membrane/paper(B)/paper(A)/anode. Set the voltage at 
maximum allowed by blotting device, and current at 2mA/cm2, for 45min. Thereafter, the 
transfer unit was disassembled, and the blot went through blocking step by incubating with 
5% BSA-containing TBST (TBST: 1×TBS with 0.1% TweenⓇ 20) on the shaker at RT for 
1h. Then the blot was incubated with primary and secondary antibodies, before being 
scanned by LI-COR Odyssey imaging system. Primary antibody incubation took 2h at RT 
or overnight at 4℃, whereas secondary antibody incubation took 1h at RT. After each 
antibody incubation, the blot was washed with TBST 3 times.  
 
5.2.4.3 Protein quantification 
Spectrophotometer NanoDrop provides UV/Vis measurement mode that conveniently 
determines protein concentrations according to the Lambert-Beer law: A = ε	 × 	b	 × 	c,                                                          (6.1) 
where A represents measured absorbance, ε represents extinction coefficient, b is path 
length and c is protein concentration. ε is wavelength- and protein sequence-dependent. 
Details for protein concentration determination are listed below (Table 5.6). Routinely, 
protein absorption at 280nm was utilized to determine concentration. In several cases 
(calmodulin, JM and JMsc), there is no tryptophan in protein, which means computed ε at 
280nm is not accurate, so another approach based on 214nm absorption of amide bonds 
was employed. In the case of EGFRΔC, absorption of TritonⓇ X-100 at 280nm interferes 
with NanoDrop measurement, so western blot analysis was performed to quantify protein 
concentration.  
In the case of fluorescent-labeled proteins, fluorophores typically have strong absorption 
at 280nm, so absorbance of protein should be corrected to remove the fluorophore 
absorption at 280nm. Thus in protein concentration determination using Lambert-Beer 
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law, A is actually calculated as A280 − A650 × correction factor, where A650 is the maximum 
absorbance of fluorophores at 650nm and correction factors are listed below (Table 5.7). 
Meanwhile, fluorophore concentrations can be computed from Lambert-Beer law as well, 
using A650 and ε650. Degree of labeling for each labeled protein was then calculated as 
ratio of fluorophore concentration to protein concentration. It indicates number of 
fluorophore per protein molecule on average.  
Table 5.6 Summary of protein concentration determination 
Protein Method  Detection wavelength  
Extinction coefficient 
(M-1 cm-1) * 
EGFRΔC Western blot   —   — 
HTint-ICDΔJM27** NanoDrop 280nm 68300 
MBPT-ICD NanoDrop 280nm 136140 
MBPT-ICD998 NanoDrop 280nm 120210 
MBPT-ICD998(4CSA S744C)  NanoDrop 280nm 120210 
MBPT-ICD998(I682Q)  NanoDrop 280nm 120210 
MBPT-ICD998(V924R)  NanoDrop 280nm 120210 
HT-ICD** NanoDrop 280nm 68300 
HT-ARNO** NanoDrop 280nm 45380 
HT-ARNO-PH** NanoDrop 280nm 29450 
HT-Sec7** NanoDrop 280nm 12950 
HT-Sec7(4A)** NanoDrop 280nm 11460 
HT-ARNOΔPBR** NanoDrop 280nm 45380 
HT-Calmodulin** NanoDrop 214nm 214835 
MBPT-JM** NanoDrop 214nm 49684 
MBPT-JMsc** NanoDrop 214nm 49684 
* Extinction coefficients at 280nm were computed using ExPaSy ProtParam tool 
(https://web.expasy.org/protparam/). Extinction coefficients at 214nm were calculated as described (Kuipers 
and Gruppen, 2007). 
** For these constructs, extinction coefficients are based on protein sequences after TEV cleavage. 
 
Table 5.7 Spectroscopic parameters of fluorophores 
Fluorophore Correction factor ε650 (M-1 cm-1)   
Alexa FluorTM 647 0.03 239,000 
RED 2nd generation 0.04 195,000 
 
5.2.5 Protein activity assays 
5.2.5.1 Autophosphorylation assay 
Autophosphorylation assay was performed in non-binding 96-well plate. EGFR constructs 
were pretreated by 40nM YopH to dephosphorylate phosphotyrosines at RT for 5min, 
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followed by 1mM Na3VO4 treatment to terminate YopH. After RT incubation with Na3VO4 
for 3min, autophosphorylation was started by incubating proteins in reaction buffer (20mM 
HEPES pH7.6 @4℃, 50mM NaCl, 5mM MgCl2, 1mM ATP), except that reaction buffer for 
EGFRΔC contains 0.1% TritonⓇ X-100. At indicated time-points, reaction was terminated 
by mixing immediately with SDS-PAGE loading buffer (supplemented with 25mM EDTA) 
and incubating on block heater for 5min. Protein phosphorylation was visualized via 
western blot immunodetection in which phosphorylated protein was detected by pY or 
pY992 antibody (anti-phosphotyrosine), while total protein was detected by anti-MBP, anti-
EGFR antibody or Streptavidin.  
5.2.5.2 Guanine nucleotide exchange assay 
ARNO-Sec7 acts as GEF upon GTPase such as Arf1, switching it from GDP-bound to 
GTP-bound state. Such structural switch of Arf1 results in change of intrinsic tryptophan 
fluorescence intensity, which is detected by Tecan plate reader.  
First, GTP, Arf1 and ARNO mixtures were prepared as follows: 
GTP mix    
 Volume  Stock concentration Working concentration 
DPBS + 3mM MgCl2 4975 μL    —    — 
GTP 25 μL 100 mM 500 μM 
    
Arf1 mix     
 Volume Stock concentration Working concentration  
DPBS 676.5 μL    —   — 
His-NΔ17Arf1 8.25 μL 136.22 μM 1.5 μM  
EDTA pH8 @4℃ 3 μL 500 mM 2 mM 
GDP 60 μL 1000 μM 80 μM  
    
ARNO mix    
 Volume Stock concentration Working concentration 
DPBS + 3mM MgCl2 496.25 μL   —    — 
ARNO constructs 3.75 μL 8 μM 60 nM 
 
Arf1 mixture with total volume of 747.75μL was incubated at 37℃ with shaking for 15min, 
to unload intrinsically bound nucleotide. Then 2.25μL of 1M MgCl2 was added to the 
mixture, followed by incubation for 5min at 37℃, to facilitate binding of external GDP to 
Arf1.  
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Thereafter, 20μL ARNO mix was combined with 25μL Arf1 mix and 45μL reaction buffer 
(DPBS + 3mM MgCl2) in non-binding 96-well plate. Exchange reaction was started by 
dispensing 10μL GTP mix into each well and tryptophan fluorescence change was 
monitored by plate reader every 10 second for 15min. Fluorescence curves were plotted 
using GraphPad PrismⓇ, and exchange activities of various ARNO constructs were 
compared.  
5.2.6 Microscale thermophoresis assay 
MST offers a quantitative way of analyzing protein-protein interaction, a method that is 
less time-consuming, immobilization-free and requires minimal protein consumption. 
Thermophoresis refers to the phenomenon in which different kinds of particles (here 
protein molecules) move along temperature gradient at different speeds, depending on 
charge, size, conformation or hydration shell of the moving particles. A generic MST 
scheme is illustrated in Figure 5.2.  
 
 
Figure 5.2 MST scheme. (A) Setup of an MST measuring device. In brief, infrared (IR) laser is 
reflected by IR Mirror and shines upon the middle points of capillaries, creating a temperature 
gradient. Meanwhile, fluorescence change due to particle thermophoresis is monitored at specific 
excitation and emission wavelengths depending on the fluorophore. (B) One example of 
thermophoretic time trace. At 5 second, IR laser is turned on to start thermophoresis, and particles 
diffuse away from middle point of capillaries. At the end of MST phase, when IR laser is turned off, 
particles start to diffuse back. Figure is taken from Jerabek-Willemsen et al., 2011. 
Principle of MST is well explained in Seidel et al., 2013. When thermophoresis starts, 
fluorophore-labeled particles begin to move along temperature gradient created by IR 
laser, leading to decreased concentration in the focus of the IR laser where fluorescence 
is monitored. In Figure 5.2, relative fluorescence intensity at a chosen time point after “IR-
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Laser on” is denoted as F1, whereas the relative fluorescence intensity right before “IR-
Laser on” is denoted as F0. The time points of F1 and F0 are also referred to as hot cursor 
and cold cursor. Then Fnorm is defined as: F*+,- = ./.0                                   .                     (5.1) 
In a typical MST assay setup for protein-protein interaction, one of the protein is 
fluorescent-labeled and held at constant concentration, while the other is unlabeled and 
serially diluted, which is referred to as “ligand” in the MST analysis software. If one of the 
factors (size, charge, protein conformation or hydration shell) is changed upon binding, 
Fnorm is typically changed as well, which means Fnorm,bound differs from Fnorm,unbound, and they 
are the signatures of two distinct species, i.e. labeled protein-ligand complex and labeled 
protein alone. In reality, MST sample is a mixture of these two species and Fnorm is the 
linear combination of Fnorm,unbound and Fnorm,bound as shown below (5.2), where FB means 
fraction bound of labeled protein.   F*+,- = 	 (1 − FB)F*+,-,7*8+7*9 +	(FB)F*+,-,8+7*9                        (5.2) 
In the following mathematical deduction, A represents unlabeled protein while B 
represents labeled one. In a 1:1 protein interaction equilibrium (5.3), dissociation constant 
Kd is calculated as in formula (5.4), where [AB] represents concentration of complex AB, 
while [A] and [B] represent total input concentrations of A and B. AB ⇌ A + B                                                         (5.3) K9 = [>]@ABB[C]@ABB[>C] = ([>]D[>C])([C]D[>C])[>C]                                         (5.4) 
The equation is solvable and solution for fraction bound of B is expressed as follows: FB = [>C][C] = [>]E[C]EFGDH([>]E[C]EFG)IDJ[>][C]K[C]                                   (5.5) 
On the right-hand side of formula (5.5), only Kd is unknown, while on the left-hand side, 
FB is linearly related to Fnorm (5.2) which can be calculated directly from experimental 
data. Hence Kd can be fitted based on the obtained data.  
For each MST assay, unlabeled protein was used to prepare 15-step serial dilution with 
final volume of 5μL in assay buffer (20mM HEPES pH7.8 @4℃, 150mM NaCl, 0.005% 
TritonⓇ X-100, 10μM BSA). Next, 5μL of 200nM fluorescent-labeled protein was added to 
each dilution. For the ICD:CaM interaction, ICDΔJM27:CaM interaction and calmodulin 
competition assay, 2mM CaCl2 or 2mM EGTA was added to the assay buffer. The 
calmodulin titration was performed in 1:2 serial dilutions, while Sec7 titration was 
performed in 1:3 dilutions. For the calmodulin competition assay, 30μM calmodulin was 
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premixed with 200nM labeled protein, before being added to 15 serial dilutions of ARNO-
Sec7. Mixed samples were loaded into Monolith NT.115 premium capillaries and MST 
measurements were performed on Monolith NT.115 system at 25℃. For assays using 
labeled Sec7 and Sec7(4A), samples were pre-incubated at room temperature for 10min 
and measured with 60% excitation power, 50% MST power. For assays using labeled ICD 
and ICDΔJM27, samples were pre-incubated at room temperature for 5min and measured 
with 20% excitation power, 40% MST power. Sample preparation and measurement were 
repeated in triplicate, and data from each protein pair were grouped together for the 
analysis, which was performed using MO.Affinity Analysis v2.3. For the calculation of 
Fnorm, hot cursor was set at 5 seconds for assays including labeled Sec7 and Sec7(4A), 
while for assays including labeled ICD and ICDΔJM27, hot cursor was set at 2.5 seconds. 
Data fitting was conducted using “Dose Response Fit” module with Kd Model. Generated 
fitting result is displayed as Fnorm vs. ligand concentration. For more convenient 
comparison of different samples, final results are converted to ΔFnorm mode by subtracting 
Fnorm,unbound from each curve using the “Compare Results” module. Exported data from 
“Compare Results” module were used for graph preparation in PrismⓇ 7.0a. 
5.2.7 EPR 
5.2.7.1 CW-EPR 
The PDsl-bound EGFR samples were loaded into 10µl glass capillaries (0.6mm inner 
diameter). The capillaries were sealed with glue to avoid leaking of the sample. 
Continuous wave EPR spectra were then recorded on an EMXnano X-band EPR 
Spectrometer from Bruker (Billerica, MA). The samples were measured at room 
temperature with a microwave power of 2.5mW, a video amplifier gain of 30dB, a 
modulation amplitude of 1G, a time constant of 81.9ms, a conversion time of 82.05ms, 
and a resolution of 10 points per G. 
5.2.7.2 PELDOR 
PELDOR data in this thesis were collected as described (Yin et al., 2017). 
5.2.8 Analytical gel filtration 
Analytical gel filtration chromatography in this thesis was performed as described (Yin et 
al., 2017). 
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6 Appendix 
6.1 Protein sequences and parameters 
Affinity tags are underlined for all constructs, and cleavage sites are indicated by asterisks 
for cleaved constructs. 
EGFRΔC (SBP-tagged): 
MW: 117021.35, pI: 6.39, ε280 = 116200 M-1cm-1 
LEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLI
ALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCN
VESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGR
CRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKY
SFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSL
SINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLH
AFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQ
KTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFV
ENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAG
HVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLR
RLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELR
EATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLL
NWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKW
MALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMV
KCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDA
DEYLIPQQGGVPENLYFQGMDEKTTGWRGGHVVEGLAGELEQLRARLEHHPQGQREPSG 
MBPT-ICD: 
MW: 102870.94, pI: 5.46, ε280 = 136140 M-1cm-1 
MAMKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWA
HDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWE
EIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLV
DLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVL
SAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEI
MPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTSSGENLYFQGSRRRHIVRKRTLRRLLQE
RELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSP
KANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCV
QIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALES
ILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMI
DADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIP
QQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTF
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LPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNST
FDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA 
MBPT-ICD998: 
MW: 82342.54, pI: 5.63, ε280 = 120210 M-1cm-1 
MAMKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWA
HDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWE
EIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLV
DLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVL
SAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEI
MPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTSSGENLYFQGSRRRHIVRKRTLRRLLQE
RELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSP
KANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCV
QIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALES
ILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMI
DADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIP
QQG 
MBPT-ICD998(I682Q): 
MW: 82357.51, pI: 5.63, ε280 = 120210 M-1cm-1 
MAMKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWA
HDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWE
EIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLV
DLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVL
SAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEI
MPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTSSGENLYFQGSRRRHIVRKRTLRRLLQE
RELVEPLTPSGEAPNQALLRQLKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATS
PKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWC
VQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALE
SILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCW
MIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYL
IPQQG 
MBPT-ICD998(V924R): 
MW: 82399.60, pI: 5.69, ε280 = 120210 M-1cm-1 
MAMKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWA
HDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWE
EIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLV
DLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVL
SAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEI
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MPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTSSGENLYFQGSRRRHIVRKRTLRRLLQE
RELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSP
KANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCV
QIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALES
ILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMRKCWMI
DADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIP
QQG 
MBPT-ICD998(4CSA/S744C): 
MW: 82262.36, pI: 5.63, ε280 = 120210 M-1cm-1 
MAMKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWA
HDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWE
EIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLV
DLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVL
SAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEI
MPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTSSGENLYFQGSRRRHIVRKRTLRRLLQE
RELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSP
KANKEILDEAYVMACVDNPHVSRLLGIALTSTVQLITQLMPFGSLLDYVREHKDNIGSQYLLNWCV
QIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALES
ILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPIATIDVYMIMVKCWMI
DADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIP
QQG 
ARNO (His-tagged): 
Before TEV cleavage, MW: 48583.26, pI: 5.71 
After TEV cleavage, MW: 46690.23, pI: 5.43, ε280 = 45380 M-1cm-1  
MGSHHHHHHENLYFQ*GSMEDGVYEPPDLTPEERMELENIRRRKQELLVEIQRLREELSEAMSEV
EGLEANEGSKTLQRNRKMAMGRKKFNMDPKKGIQFLVENELLQNTPEEIARFLYKGEGLNKTAIG
DYLGEREELNLAVLHAFVDLHEFTDLNLVQALRQFLWSFRLPGEAQKIDRMMEAFAQRYCLCNPG
VFQSTDTCYVLSFAVIMLNTSLHNPNVRDKPGLERFVAMNRGINEGGDLPEELLRNLYDSIRNEPF
KIPEDDGNDLTHTFFNPDREGWLLKLGGGRVKTWKRRWFILTDNCLYYFEYTTDKEPRGIIPLENL
SIREVDDPRKPNCFELYIPNNKGQLIKACKTEADGRVVEGNHMVYRISAPTQEEKDEWIKSIQAAVS
VDPFYEMLAARKKRISVKKKQEQP 
ARNO-PH (His-tagged): 
Before TEV cleavage, MW: 15812.86, pI: 6.65 
After TEV cleavage, MW: 13919.83, pI: 6.80, ε280 = 29450 M-1cm-1 
MGSHHHHHHENLYFQ*GSDREGWLLKLGGGRVKTWKRRWFILTDNCLYYFEYTTDKEPRGIIPLE
NLSIREVDDPRKPNCFELYIPNNKGQLIKACKTEADGRVVEGNHMVYRISAPTQEEKDEWIKSIQAA
VSVD 
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Sec7 (His-tagged): 
Before TEV cleavage, MW: 23536.92, pI: 6.50 
After TEV cleavage, MW: 21643.88, pI: 6.38, ε280 = 12950 M-1cm-1 
MGSHHHHHHENLYFQ*GSRNRKMAMGRKKFNMDPKKGIQFLVENELLQNTPEEIARFLYKGEGL
NKTAIGDYLGEREELNLAVLHAFVDLHEFTDLNLVQALRQFLWSFRLPGEAQKIDRMMEAFAQRY
CLCNPGVFQSTDTCYVLSFAVIMLNTSLHNPNVRDKPGLERFVAMNRGINEGGDLPEELLRNLYD
SIRNEPFKIP 
Sec7(4A) (His-tagged): 
Before TEV cleavage, MW: 23266.53, pI: 6.50 
After TEV cleavage, MW: 21373.50, pI: 6.38, ε280 = 11460 M-1cm-1 
MGSHHHHHHENLYFQ*GSRNRKMAMGRKKFNMDPKKGIQFLVENELLQNTPEEIARFLYKGEGL
NKTAIGDYLGEREELNLAVLHAFVDLHEFTDLNLVQALRQFLWSFRLPGEAQKIDRMMEAFAQRY
CLCNPGVFQSTDTCAVLSAAVAALNTSLHNPNVRDKPGLERFVAMNRGINEGGDLPEELLRNLYD
SIRNEPFKIP 
ARNOΔPBR (His-tagged): 
Before TEV cleavage, MW: 46848.15, pI: 5.29 
After TEV cleavage, MW: 44955.12, pI: 5.07, ε280 = 45380 M-1cm-1 
MGSHHHHHHENLYFQ*GSMEDGVYEPPDLTPEERMELENIRRRKQELLVEIQRLREELSEAMSEV
EGLEANEGSKTLQRNRKMAMGRKKFNMDPKKGIQFLVENELLQNTPEEIARFLYKGEGLNKTAIG
DYLGEREELNLAVLHAFVDLHEFTDLNLVQALRQFLWSFRLPGEAQKIDRMMEAFAQRYCLCNPG
VFQSTDTCYVLSFAVIMLNTSLHNPNVRDKPGLERFVAMNRGINEGGDLPEELLRNLYDSIRNEPF
KIPEDDGNDLTHTFFNPDREGWLLKLGGGRVKTWKRRWFILTDNCLYYFEYTTDKEPRGIIPLENL
SIREVDDPRKPNCFELYIPNNKGQLIKACKTEADGRVVEGNHMVYRISAPTQEEKDEWIKSIQAAVS
VDPFYEMLAA 
ICD (His-tagged): 
Before TEV cleavage, MW: 63140.71, pI: 6.01 
After TEV cleavage, MW: 61304.73, pI: 5.85, ε280 = 68300 M-1cm-1 
MSHHHHHHENLYFQ*GARRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVL
GSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTST
VQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQH
VKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYD
GIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDE
RMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACID
RNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNP
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APSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEA
KPNGIFKGSTAENAEYLRVAPQSSEFIGA 
HTint-ICDΔJM27: 
Before TEV cleavage, MW: 63729.39, pI: 6.01 
After TEV cleavage, MW: 57785.56, pI: 5.34, ε280 = 68300 M-1cm-1 
MASSHHHHHHIEGRCRRRHIVRKRTLRRLLQERELVEPLTPSENLYFQ*GEAPNQALLRILKETEFK
KIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGIC
LTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKT
PQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSK
PYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQ
GDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTV
ACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQ
PLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFF
PKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA  
MBPT-JM: 
Before TEV cleavage, MW: 46122.61, pI: 5.67 
After TEV cleavage, MW: 4572.39, pI: 11.91, ε214 = 49684 M-1cm-1 
MAMKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWA
HDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWE
EIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLV
DLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVL
SAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEI
MPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTSSGENLYFQ*RRRHIVRKRTLRRLLQER
ELVEPLTPSGEAPNQALLRI 
MBPT-JMsc: 
Before TEV cleavage, MW: 46122.61, pI: 5.67 
After TEV cleavage, MW: 4572.39, pI: 11.91, ε214 = 49684 M-1cm-1 
MAMKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWA
HDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWE
EIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLV
DLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVL
SAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEI
MPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTSSGENLYFQ*RELKHIQVRLRTERQLEPL
EIRAVNRSRLTPRLAGLPR 
Calmodulin (His-tagged): 
Before TEV cleavage, MW: 18599.43, pI: 4.35 
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After TEV cleavage, MW: 16706.39, pI: 4.09, ε214 = 214835 M-1cm-1 
MGSHHHHHHENLYFQ*ADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQ
DMINEVDADGNGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGE
KLTDEEVDEMIREADIDGDGQVNYEEFVQMMTAK 
6.2 Uncorrected PELDOR time traces from EPR study 
 
Figure S1 Uncorrected PELDOR time traces of all EGFR constructs used in conformation study. In 
each graph, red curve denotes the background function, while magenta arrow marks the zero 
measurement time point.  
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6.3 Individual data points from MST assay 
 
Figure S2 Individual MST measurements are grouped as protein interaction pairs. MST of each 
pair was repeated in triplicate and plotted as scatter graph. CaM: calmodulin.  
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